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Introduction 
Transmissible spongiform encephalopathies 
Transmissible spongiform encephalopathies (TSEs) are a group of rare neurodegenerative 
diseases that affect several mammalian species, including humans (Table 1). These diseases are 
characterized by the spongiform degeneration of the brain tissue (Figure 1A), loss of neurons 
which cause cognitive and motor dysfunctions, depending on which regions of the nervous 
system are affected. Astrogliosis and sometimes amyloid plaque formation can also be detected 
in the TSE brain. These diseases are currently untreatable and progressive, always resulting in 
the death of the affected host. 
 
HOST DISEASE 
HUMAN Kuru, 
“Classic” Creutzfeldt-Jacob Disease, 
Gerstmann–Sträussler–Scheinker syndrome (GSS), 
Fatal familiar insomnia (FFI), 
Fatal sporadic insomnia (FSI), 
variant CJD 
atypical CJD 
OVINE Scrapie 
BOVINE Bovine spongiform encephalopathy (“mad-cow disease”, BSE) 
ELK, DEER Chronic wasting disease (CWD) 
FELINE Feline spongiform encephalopathy 
MINK Mink spongiform encephalopathy 
GREATER 
KUDU, 
NYALA, 
ORYX 
Exotic ungulate encephalopathy 
Table 1: Mammalian host species and their respective transmissible spongiform 
encephalopathies 
 
Human prion diseases are very rare. The prevalence of Creutzfeldt-Jacob disease (CJD), the 
most common human TSE, is about 1-9/1000000. Two other familiar prion diseases, fatal 
familiar insomnia (FFI) and Gerstmann–Sträussler–Scheinker syndrome (GSS) are even rarer, 
prevalence of FFI is about 1/1000000, and is unknown in case of GSS. As comparison, 
Parkinson’s disease affects 1% of the population over 55 years of age (1), and about 4% of the 
population over 65 years is affected by Alzheimer’s disease (2). 
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“Classic” (as opposed to “variant”, see below) Creutzfeldt-Jacob disease (CJD) was the first 
human TSE described (Creutzfeldt, 1920 and Jacob, 1921), but the cause of the disease has 
been found only half a century later. CJD, like Parkinson and Alzheimer, is typically a disease 
of the older generations. 
  F  
Figure 1: (A-E) Histological sections of TSE-affected (A, B) or healthy (C, D) brains and Swiss 
cheese (E). Presence of vacuolization (white spherical areas) and extracellular plaques (brown 
staining) are apparent. (F) Scrapie affected sheep (3) 
[Source of (A-E): https://biogeekery.wordpress.com/2013/01/28/prions-pestiferous-proteins/]  
 
“Classic” CJD has three forms: about 85% of the cases are sporadic, 10% are familiar, where 
the disease is associated with a gene mutation and 5% are iatrogenic, where the disease is 
acquired with accidental transmission via improperly sterilized surgical tools, or transplants of 
dura mater or cornea fragments, or administration of pituitary hormones of cadaveric origin. 
Among the human TSE-s, kuru should also be mentioned, both as a curiosity and as the 
disease that led to the discovery of the infectious nature of TSEs. Kuru was an endemic disease 
that decimated the Fore tribe in Papua New Guinea. It has been described by Charleton 
Gajdusek in the middle of the 20th century, who connected it to the funerary cannibalism 
practiced by the tribe. Despite not having found evidence of parasitic, viral or bacterial 
infection, he assumed the disease to be infectious. It took a decade for him and his colleagues 
to prove the concept in primates: the injection of brain homogenates of kuru patients into 
healthy monkeys caused appearance of TSE symptoms in the animals (4).  
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Despite the rarity of the human TSE-s, the public health and economic issues of the ovine 
and bovine TSEs (Scrapie and BSE, respectively) in the past centuries highlighted the 
importance of understanding this family of diseases. 
Scrapie is a natural disease of sheep and goats. It is known since 17-18th centuries and 
caused economical problem, since the disease is capable of spreading rapidly within and 
between flocks. The name of the disease originates from one of the most prominent symptoms: 
the affected animals develop a compulsive rubbing behaviour, scrape and chew their wool and 
skin off (Figure 1B). 
Although sporadic cases of bovine spongiform encephalopathy (BSE) or “mad-cow disease” 
symptoms have been recorded since the 5th century B.C. (5), the disease became well-known 
with the significant economical and health crisis it caused two decades ago in the 1990s BSE 
outbreak in Great-Britain and in several other western countries (6, 7).  
Evidences were found that affected animals were exposed to TSE infection, either scrapie or 
sporadic BSE, during their calfhood via ruminant-derived foodstuff. As a consequence millions 
of cattle had to be slaughtered and it have also led to stricter regulations of ruminant feeding. 
The other implication of the BSE outbreak was the appearance of “variant” CJD (vCJD) (8).  
Strong evidences indicate that vCJD is linked to bovine spongiform encephalopathy (BSE) 
and the consumption of BSE meat was the cause of the appearance of vCJD (9). Since the first 
case, described in 1995, a few hundred patients have been diagnosed with the disease. There 
were several differences between the symptoms of CJD and vCJD. The latter affected younger 
people than “classic” CJD [median age of 28 (vCJD) vs. 68 (CJD) years], had relatively longer 
incubation time (13-14 months instead 4-5), and the first clinical symptoms were different 
(dementia and early neurologic signs in CJD, whereas psychiatric anomalies, behavioural 
problems and delayed neurologic signs in vCJD).  
 
Mechanism of TSE transmission 
The first hypothesis for the mechanism of infection was the controversial “slow virus 
hypothesis”, suggesting that despite the missing evidence of viral infection, slow-acting viruses 
would cause TSEs, after a long incubation period (10). 
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Several discoveries led to a new, heretical hypothesis called the prion hypothesis that 
suggested that TSE are caused by “prions”, a new genre of disease causing agents that consist 
of proteinaceous infectious particles and no nucleic acids were needed for the disease 
propagation. The word “prion” comes from protein and infection (11).  
The infectious agent is mainly composed of PrPSc, an abnormal conformational isoform of 
the cellular prion protein, or PrPC. It also contains polysaccharides and lipids, but nucleic acids 
that were more than 25 nucleotide long were below the detection limit, disputing the slow virus 
hypothesis (12). Moreover aggregations of PrPSc have also been detected in TSE-related 
amyloid plaques. 
 
Prion protein (PrP) 
Expression and structure of prion protein 
Prion protein is ubiquitously expressed as a cell surface glycoprotein, showing the highest 
expression levels in neurons of the brain and spinal cord, although it is also expressed in other 
cell types of the CNS and in other tissues (13, 14). The protein is encoded by the prnp gene that 
lies in the PRN locus (human chromosome 20, mouse chromosome 2).  
The expressed polypeptide is about 255 amino acids long in humans, and slightly variable 
in other species (254 in mice). During protein synthesis N-terminal signal peptide of the protein 
is recognized by the signal recognition particle (SRP) and the nascent protein is directed to the 
secretory pathway where the protein folds and undergoes several modifications and at the end 
it is transferred onto a GPI-anchor from its C-terminal GPI-anchor signal, and the N-
glycosylation occurs. Going through the secretory pathway the mature prion protein is delivered 
to the cell surface, where it localizes predominantly in the lipid raft compartment. The 
molecular weight of the mature protein without the glycan side chains is about 23 kDa. 
The protein consists of two major regions, a globular C-terminal domain and a flexible N-
terminal tail (Figure 2) which evolved independently from one another (15). The C-terminal 
domain, despite its high sequence divergence among species, retained its basic 3D structure, 
containing 3 -helices and 2 -sheets, and the protein is stabilized by a disulphide bond between 
the helix 2 and 3. There are two N-glycosylation sites on the C-terminal domain: the mature 
PrP can be non-, mono-, and diglycosylated. The N-terminal tail of the protein is partially 
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unstructured or disordered and consists of four regions, which are the following: a 6 amino-
acid long extreme N-terminal charged cluster (CC1), a repeat containing motif of a 8 amino 
acids, called octarepeat region (OR), another charged cluster (CC2), which is followed 
immediately by a hydrophobic domain (HD).  
 
Role of prion protein in TSE 
The key event of TSE pathogenesis is the conversion of the host’s own PrPC molecules into 
the pathological PrPSc isoform where PrPSc molecules serve as template for the conversion 
process (11, 14). 
In vitro three PrPSc binding sites have been identified on PrPC, 23-33 and 98-110 amino acid 
segments on the N-terminal tail, and the third on the C-terminal domain (16). 
Although the native C-terminal domain of PrPC consists of three alpha-helices, PrPSc is a 
beta-sheet rich conformational isoform of the prion protein. Even though the high resolution 
3D structure of PrPC has been determined by NMR, that of the PrPSc is still debated (17). PrPSc 
is prone to oligomerization and aggregation, insoluble in non-ionic detergents and has an 
increased protease resistance. A 2 hours treatment with 50 g/ml Proteinase-K (PK) at 37°C 
cannot digest completely the PrPSc, a PK-resistant C-terminal core of the PrPSc molecule 
remains intact unless subjected to a more vigorous proteinase treatment. This partially PK-
resistant core retains the ability to convert PrPC to PrPSc, thus it keeps its infectivity. 
There are several experiments underlining the importance of the host’s own PrPC in TSE 
progression. One of the most straightforward evidence of PrPC importance in TSE is that prnp 
knockout mice are resistant to TSE and the disease can’t be propagated in them: after 
inoculation of PrPSc these mice show neither signs of neurodegeneration nor reduced lifespan 
(18). 
Neuron-specific ablation of PrP expression with cre-lox system in mice 8 weeks after being 
inoculated with PrPSc also prevented neurodegeneration. In these mice amyloid plaques and 
PrPSc were detectable in the brain tissue, but early spongiform changes were reversed and the 
mice didn’t develop signs of neurodegeneration (19). 
In a third experimental setup, nerve tissue grafts, overexpressing PrPC, were implanted into 
brains of PrP KO mice and these mice were inoculated also with PrPSc. The PrPC expressing 
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grafts propagated PrPSc and developed lesions typical in TSE, but neighbouring PrP KO tissues 
showed no signs of neurodegeneration (20). 
The importance of the cell surface localization of PrP in TSE pathogenesis has also been 
demonstrated. Mice expressing GPI-anchorless PrP instead of wild type PrP (WT-PrP) were 
inoculated with PrPSc. In these mice extracellular amyloid plaque formation and PrPSc 
generation was detected, and the de novo generated PrPSc could be used to propagate the disease 
in other mice, but despite the presence of PrPSc in the central nervous system (CNS) of the GPI-
anchorless PrP expressing mice no signs of neurodegeneration could be observed (21).  
Although there is a consensus regarding the involvement of PrP in TSE pathogenesis, the 
mechanism of the conversion from the native cellular form into the pathogenic form that results 
in cell death is still debated. Since the presence of PrPSc in a PrPC-less environment doesn’t 
cause neurodegeneration, it is reasonable to assume that the toxicity is mediated by either PrPC, 
or an intermediary conformation of the conversion. 
PrP knock-out animal models suggest that the lethal phenotype is not caused by a loss of a 
kind of vital function of the prion protein as neither pre- nor postnatal ablation of PrPC resulted 
in a lethal phenotype. 
As PrPSc and amyloid plaques are still present in mice where endogenous PrPC ablated post-
inoculation, without causing any neurodegeneration, the possibility that the neurodegeneration 
is caused merely by PrPSc gaining a novel, toxic function can also be excluded. 
According to a third hypothesis, the neurodegeneration is caused by the subversion or 
corruption of a normal, physiological function of the PrPC due to the conformation change, or 
the presence of PrPSc somehow alters a signalization pathway affected by PrPC. 
 
Physiological functions of the prion protein family members 
Even though the evolutionary conserved structure suggests an evolutionary conserved 
function of the protein which is probably important, knocking out the prnp gene didn’t result 
in a lethal phenotype (22, 23), although PrP null mice show minor abnormalities. Studying 
knockout animals proposed the involvement of PrP in various physiological processes (24), 
notably normal olfactory behaviour and physiology (25), hippocampus-dependent spatial 
learning (26), and peripheral myelin maintenance (27). 
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Ligands and interactions of the prion protein 
As a GPI-anchor protein, PrP probably have some interacting partners in postulated 
signalization cascades. In fact the protein seems to be rather promiscuous, in the past three 
decades passed from cloning of the human prion protein (28) several partners (29) have been 
found to interact with PrP, and various functions were associated to several regions of the 
protein, but the exact physiological function of the prion protein remained elusive. The binding 
partners of PrP include the following examples, as reviewed in (30): 
Copper: N-terminal region of the PrP has 5 Cu2+-binding sites, among 4 in the OR. 
Lipids: PrP can form hydrophobic interactions with lipid vesicles independent of its GPI-
anchor with its CC1, CC2 and hydrophobic domains. CC1 was also reported to be acting as a 
transduction domain, and the HD may act as transmembrane domain under certain conditions. 
Heparan sulphate: These molecules were detected in amyloid plaques found in GSS, CJD 
and Scrapie-brains. Surface plasmon resonance and ELISA studies demonstrated that the CC1, 
OR and the HD were responsible for heparan sulphate binding. 
Nucleic acids: In certain experimental conditions recombinant PrP was found to be able to 
bind DNA and RNA in vitro. The CC1, CC2 and the OR regions of the N-terminal domain are 
required for the binding. No functions have been associated to the nucleic acid binding activity 
of the protein, but the reports of nuclear localization of the PrPC along with two GSS associated 
deletion mutant PrP-s that also showed nuclear localization suggest a potential physiological or 
pathological role of PrP in the nucleus. 
 
CC1 region is also critical for the endocytosis of the protein via clathrin-coated pits, it was 
found to be a binding site of the endocytic receptor LRP1 protein (31). 
Physiologically the protein may undergo cleavages named alpha or beta cleavage. The alpha 
cleavage site is after the 110th amino acid residue, between CC2 and HD. Proteolytic processing 
in this case results in the release of an N1 (N-terminal) fragment, and the C-terminal C1 
fragment remains membrane-bound. Beta cleavage happens at residues 90-91, after the OR 
region, resulting in an N2 and C2 fragments (32). 
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Interestingly several cytotoxic and protective functions have been associated to the CC1, 
CC2 and HD of PrP. Understanding these activities might help to understand how 
neurodegeneration occurs during TSE. 
 
Toxic activities of the prion protein 
While the GPI-anchorless PrP expressing mouse demonstrated that prion propagation was 
possible without neurodegeneration, other experiments showed that neurodegeneration could 
also be caused without the presence of any infectious agent. 
During search for the minimal essential PrP fragment required for TSE pathogenesis, 
Weismann and colleagues have found that the expression of certain deletion mutant PrP 
transgenes that lacked part of their N-terminal tail, led to progressive ataxia and degeneration 
in the cerebellar granular layer of prnp knockout mice (33). The deletion of the N-terminal 
domain of PrP became toxic when it included part or the whole of the hydrophobic domain 
(HD) of PrP (111-131st amino acids in mouse PrP): PrP32-106 was not, but PrP32-121 or 
PrP32-134 were toxic (these deletion mutant PrP-s have been named “Shmerling-mutants”).  
Deletion of the so called “Central Region” of the protein, a region that overlaps with PrP 
CC2 and the HD (105-125th amino acids in mouse PrP), produced a similar phenotype to 
Shmerling-mutants, but the phenotype was more severe extent (34). Mice showed symptoms 2 
weeks after birth and also died earlier. Also a relatively much higher expression of wild-type 
PrP is required to eliminate the effect of PrPCR than that of Shmerling-mutants with similar 
expression levels. The expression of a similar construct, PrP94-134 in mice also caused a 
rapid lethality (35). 
Unlike familiar TSEs, these mutations don’t destabilize PrP leading to PrPSc formation and 
no infectious agents could be extracted from these mice. Brain homogenates of mice expressing 
Shmerling-mutants didn’t cause neurodegeneration in other mice. 
The introduction of one or more copies of wild type PrP gene to mice expressing the deletion 
mutant PrP-s abrogated the neurodegeneration. To eliminate the Shmerling-mutant-induced 
neurotoxicity, one copy of PrP or PrP32-93 was enough (36), the later suggesting that the OR 
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plays no role in the rescue effect, and the severity of HD (35) and CR PrP-induced (34) 
toxicities were reduced in a dose dependent manner. 
Not only in animal models were Shmerling-mutants toxic, but also in primary neuron 
cultures, contrary to these models, when expressed in immortalized cell lines, Shmerling-
mutant, HD or CR PrP-s have no such robust effect, or any at all.  
Interestingly, Harris and colleagues have found that both Shmerling-mutants and PrPCR 
causes increased sensitivity to certain drugs (hygromycin, G418 and Zeocin) in several types 
of immortalized cell lines of neuronal and non-neuronal origins, as well as in NSCs and CGN 
cultures (37). Kinetic studies revealed that the mutants increase the cellular uptake of both G418 
and Zeocin that could not be achieved by the modulation of ABC transporter activities. The 
presence of CC1 in both 32-134 and 105-125 mutant PrP-s is required for mediating the 
toxic signal in both animal and in the drug hypersensitivity models (38). 
PrPCR and several other HD mutants have also been found to cause spontaneous inward 
ionic currents through the plasma membranes of various cell types (39, 40), which activities 
were observed also by PrP-s harbouring familiar TSE-related point mutations. These effects, 
although not being directly toxic, were also abrogated by the co-expression of WT PrP. 
Not only the severity of the neurotoxicity differs between the deletion mutants, but there are 
differences between the neuropathology of PrP96-134 (myelin degeneration but intact 
granular layer) and PrP105-125 (degeneration in cerebellar granular layer). 
The signalization events in the course of neurodegeneration also differs in case of various 
toxic mutants. In transgenic mice it was found that PrP32-134 toxicity depends on BAX-
related pathways but also BAX-independent pathways are involved in PrPCR toxicity (41).  
Lastly the difference between the relative amounts of WT-PrP required for compensation of 
Shmerling or CR mutant PrP-s indicate differences between their mechanisms of action. 
Another difference between the behaviour of HD and CR PrP-s is found in the glutamate 
toxicity model. PrPCR, expressed in CGN or neural stem cell (NSC) cultures,  increase the 
sensitivity of the cells to glutamate (42), contrarily PrP113-133, which has no such sensitizing 
effect when expressed in the human neuroblastoma SH-SY5Y cells (43). It must be noted that 
these effects were observed in different cell types. 
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Protective activities of the prion protein 
Several functions associated to the prion protein are related to protection against certain 
stressors. In murine stroke models PrPC provided neuroprotection after ischemic insult (44). 
In cell culture and animal models PrP expression protected from the excitotoxicity of 
glutamate, kainate and NMDA. The intact N-terminal tail was required for this anti-apoptotic 
effect of the PrP, the deletion of amino acids 27-89 abrogated this protective activity of the PrP. 
It was shown that PrP has a superoxide dismutase activity, providing protection against 
oxidative stress (45). Furthermore, according to certain data in literature, immortalized cells of 
hippocampal origin expressing prion protein were more resistant to apoptosis induced by 
oxidative stress (46) and also showed higher viability and lower autophagy-marker expression 
levels during serum deprivation (47). 
Probably both oxidative stress and excitotoxicity protection is related to the copper binding 
activity of PrP and its role in the copper metabolism (48, 49). These activities require the 
presence of the N-terminal tail of the protein. 
Wild type PrP is also able to eliminate all toxic Shmerling-mutation or CR PrP effects in a 
dose dependent manner. The presence of the N-terminal tail is also important here. In cell co-
culture models it has been demonstrated that the protective effect of PrP can occur in “trans” 
mode where the protective effect of PrP manifests in adjacent cells (50).  
 
Role of the prion protein in Alzheimer disease 
Alzheimer disease (AD) is probably the most prevalent neurodegenerative disorder. In 2015 
there were about 30 million people afflicted by AD worldwide (source: http://www.who.int). 
Like TSE, AD is incurable, and fatal, symptoms include early memory deficits and dementia, 
insomnia, behavioural changes that worsen during the disease progression. 
The cause of AD is not well understood, several risk factors and genes have been identified 
and some proteins were shown to have key role in the pathogenesis [amyloid precursor protein 
(APP), Tau, presenilins, apolipoprotein E (APOE)]. 
AD is characterized by a massive neuronal cell and synapse loss as well as the formation of 
extracellular senile plaques and intracellular neurofibrillary tangles containing a 
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hyperphosphorylated form of the microtubule binding protein Tau. The main component of 
senile plaques is composed of the aggregates of A40-42, or -amyloid peptide, a 42 amino 
acid long peptide that is cleaved from APP by - and -secretases. It was suggested that A 
peptide acts primarily and triggers further downstream processes, such as tau aggregation that 
leads to neurodegeneration (51). 
More and more results highlight the possible role of PrPC in the pathogenesis of the 
Alzheimer’s disease (AD). There is direct interaction between PrPC and A40 monomers (52) 
or a subpopulation of -amyloid oligomers (A) (53) where PrP act as an A receptor (54). 
Interestingly the binding sites of A peptide overlap with the CC1 and CC2 of PrP (53). PrP 
has a dual role in AD. On one hand By binding A oligomers PrP participates in A-removal 
from the CNS through the blood-brain barrier (52). On the other hand PrP relays a toxic signal 
from A oligomers into the neurons, that can lead to synaptic impairment (55) or the inhibition 
of hippocampal LTP (53). LRP1 (56), mGlut5 receptor (57) are also involved in the toxic 
signalization pathway. 
 
Other members of the prion protein family 
Doppel protein 
The doppelganger of the prion protein, or Doppel (Dpl), is encoded by the prnd gene. The 
prnd gene lies downstream from the prnp gene, in the same locus. Evolutionary analysis 
indicates that these two genes arose from a single ancestor gene by gene duplication in an 
ancestral tetrapoda (58). 
The Doppel protein is paralog of PrP, exhibiting an average of 25% sequence identity (33). 
The Dpl precursor protein consists of 179 amino acids in mouse and 176 amino acids in humans. 
Dpl expression level is the highest in the testis and male reproductive tract, it has a role in the 
spermatogenesis (59) but Doppel protein or its mRNA has also been detected in the spleen, 
bone marrow, skeletal muscles and heart too (60). 
Dpl structure resembles to the C-terminal, globular domain of the Prion protein (Figure 2): 
the mature protein is flanked by an N-terminal signal peptide responsible for directing the 
protein to the secretory pathway and a C-terminal GPI-anchor signal. The mature protein 
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consists of a short, unstructured N-terminal tail and a globular C-terminal domain that is made 
of three a-helices, and is stabilized by two disulphide-bonds. The C-terminal domain harbours 
two N-glycosylation sites too. 
 
Figure 2: Domain 
structure of the prion 
protein family. A, B, 
C: alpha helices. Narrow, 
tall, dark green boxes: -
strands. CHO: N-
glycosylation sites. GPI: 
GPI-anchors. Red 
brackets: disulphide 
bonds. Striated grey boxes: 
charged clusters (CC1, 
CC2 in PrP, unnamed in 
Dpl and Sho). Blue boxes in PrP: Octarepeat region (OR). Striated blue boxes in Shadoo: 
(RXXX)8 region. Orange boxes: hydrophobic domains (HD). Green tones: structured region of 
PrP and Dpl. 
 
Doppel normally isn’t expressed in the CNS so this protein probably plays no role in TSE 
pathogenesis, but the absence of prnd gene in testis leads to male infertility (59). What makes 
this protein interesting is that it may acquire toxic activities similar to Shmerling-mutant PrP-s. 
The initial prnp knockout mouse showed no major deficits or neurodegeneration but another 
prnp knockout strain established by another group, after normal development, showed 
progressive ataxia and loss of Purkinje-cells in the cerebellum from the age of 70 days (61). In 
this knockout mouse the imprecise attempt of knocking out the prnp gene caused the prnp 
promoter driving the subsequent prnd coding region, thus the establishment of an ectopic 
Doppel expression in the CNS (62). Later this toxic phenotype caused by the Dpl expression in 
the absence of PrP was confirmed in transgenic mice (63) and also in primary cerebellar 
granular neuron (CGN) cultures (64). 
Interestingly the co-expression of wild type PrP seemed to antagonize the toxic effects of 
Doppel in both mice (65) and cell cultures (64): the presence of PrP eliminated the Doppel 
toxicity in these models. 
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Shadoo protein 
Shadoo of the prion protein, or Shadoo (Sho), is the latest discovered member of the prion 
protein family, encoded by the sprn gene, which localizes on a different chromosome (human 
chromosome 10, mouse chromosome 7) (66). Shadoo was first discovered in zebrafish (67), 
then in many fish, amphibians and mammalian species. 
Sprn is expressed in the neurons of the CNS, its expression pattern seems to be 
complementary with that of the prnp gene (64). Similar to Doppel, Shadoo is also considered 
as a paralog of the prion protein. Shadoo precursor protein also contains an N-terminal signal 
peptide and a C-terminal GPI-anchor signal. The protein localizes on the cell surface, although 
it has been demonstrated that akin to PrP, Shadoo is able to bind nucleic acids (68, 69) and were 
detected in nuclei too (69). 
Shadoo is an unstructured protein, resembling to the flexible N-terminal tail of PrP. Shadoo 
and PrP have similar domain organization, even though no extended sequence similarity exists 
between the two proteins. Both mature Shadoo and prion proteins begin with a positively 
charged N-terminal cluster, followed by repeated sequences (octarepeats in PrP, (RXXX)8 
motif in Sho (69) and they have similar hydrophobic regions.  
The overlapping expression patterns of Shadoo and prion proteins and the resemblance of 
the two proteins explains starting examination of the Shadoo expression in TSE brains. While 
Sho mRNA levels were unaltered or mildly elevated (70), the Shadoo protein levels were 
drastically down-regulated in later stages of TSE (64), although the extent of down-regulation 
depended on the PrPSc strain (70). 
Several publications reported frame shifts mutations in the coding region of Sprn gene 
associated to TSE susceptibility in humans (71) or in ovine (72, 73). Recently it was suggested 
that the PrP – Shadoo interaction may modify the PrP-folding pathway, and may affect the prion 
replication process (74). 
Shadoo shows not only structural similarity to the N-terminal region of PrP, but also 
functional analogy to wild type PrP. Just like WT-PrP, Shadoo is able to eliminate the toxic 
phenotypes of both Doppel and the Shmerling, or HD mutant PrP-s in primary or immortalized 
cell cultures (64). Furthermore, akin to WT-PrP, Shadoo exhibits protective effect against 
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glutamate-induced excitotoxicity in cell cultures emphasizing the neuroprotective feature of 
Sho that is also characteristic of PrP bearing an intact N-terminal part (43).  
This functional analogy between the two proteins is interesting because the sequence 
homology between Shadoo and PrP N-terminal domain is low. Both proteins are cell surface 
proteins but only their hydrophobic domains show a higher degree of similarity, suggesting that 
these segments are important for the shared cytoprotective activities of the two proteins. These 
segments were also found to be important in Sho-PrP dimerization and also the deletion of Sho 
HD abolished the protective activities of the protein. Whether Shadoo provides any protection 
against the drug hypersensitivity or eliminates the ionic currents caused by PrPCR has not 
been studied before our work.  
22 
 
 
 
Aim of this study 
As several evidences underline the hypothesis, that a toxic or protective function of the prion 
protein play role in TSE associated neurodegeneration, we studied the toxic and protective 
effects associated to the prion protein family. 
Our goal was to establish a model system where such activities of the prion protein family 
can be studied. We investigated experimental constructs of PrPs in immortalized human and 
non-human mammalian cell lines that were either prnp knock-out or had low endogenous PrP 
expression. 
 
We studied two models: 
In the first model we investigated the role of the prion protein in the effects of serum deprivation 
on cells and tried to answer the following questions: 
1. Does wild-type PrP confer any protection against serum deprivation induced apoptosis? 
2. Does PrPCR increase the sensitivity of the cells to serum deprivation? 
3. Does PrPCR expression decrease the viability to cells maintained in normal condition? 
 
In the second model system we studied the PrPCR-induced Zeocin and G418 
hypersensitivity found by the Harris-group (37). We postulated that overlapping protective 
function of Shadoo and WT-PrP from literature may have the consequence that Shadoo can also 
eliminate PrPCR-induced Zeocin and G418 hypersensitivity. Surprisingly we have found that 
Shadoo protein not only doesn’t eliminate the PrPCR-induced antibiotic-sensitivity, but 
instead induces such sensitivity. 
Based on this surprising finding have characterized further this effect of the Shadoo protein. 
In this topic we tried to answer the following questions: 
1. Can WT-PrP eliminate also the antibiotic-sensitivity caused by Shadoo protein? 
2. Which regions of Shadoo protein is required for the sensitizing activity? 
3. Similarly to PrPCR, does Shadoo induce hypersensitivity by increasing the initial drug 
uptake or by another mechanism?  
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Materials and methods 
Reagents used in the studies 
Restriction Endonucleases, T4 DNA ligase, ATP, dNTP mixture, Pfu DNA polymerase were 
purchased from Thermo Scientific. Isopropyl β-D-1 thiogalactopyranoside was purchased from 
Thermo Scientific. High-glucose Dulbecco's Modified Eagle Medium (DMEM) and fetal 
bovine serum (FBS) were obtained from Life Technologies/Gibco and Penicillin/Streptomycin 
from Lonza. TurboFect transfection reagent were purchased from Thermo Scientific.  
Zeocin and PrestoBlue reagent were obtained from Life Technologies. Geneticin (G418), 
puromycin and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were 
obtained from Sigma-Aldrich. 
Bradford-reagent was purchased from Bio-Rad. Polyvinylidene fluoride (PVDF) transfer 
membrane and chemiluminescent substrate (Immobilon ECL substrate) were from Millipore. 
Peptide-N-glycosidase F (PNGaseF) was purchased from New England Biolabs. 
Phosphatidylinositol-dependent phospholipase-C (PI-PLC) was purchased from Thermo 
Scientific (LifeTechnologies). 
All other reagents and chemicals were purchased from Sigma-Aldrich. 
Antibodies used in immunocytochemistry (ICC) and immunoblotting (WB) 
Primary antibodies and dilutions: 
SAF32 anti-PrP mouse IgG (Cayman Chemical, 189720), in 1:200 (ICC) or 1:5000 (WB). 
Purified anti H2AX.phospho antibody (Biolegend, 613402), in 1:250 (ICC). 
Anti-Shadoo rabbit polyclonal antibody (Abgent, AP4754b), in 1:200 (WB). 
Anti--actin chicken IgG (Sigma, GW23014), in 1:2000 (WB). 
Primary antibodies were diluted in IF solution (ICC) or TBST (WB), supplemented with 7 mM 
(ICC) or 2 mM (WB) NaN and were stored at 4°C after usage. 
Secondary antibodies and dilutions: 
ICC: Goat anti-mouse IgG (H+L), Alexa Fluor 594 or Alexa Fluor 647 conjugated (Life 
Technologies, A11005 and A21235) were used in 1:250 in IF. 
WB: Horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit and anti-chicken IgG 
were from Jackson ImmunoResearch (715-035-151), Pierce Biotechnology (31460) and Sigma-
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Aldrich (A9046), in 1:20000, 1:200000 and 1:200000 in blocking solution (WB) respectively. 
Secondary antibody dilutions were never reused. 
 
Plasmid constructs and DNA cloning 
DNA sequences used in the cloning processes 
The cDNA of mouse Shadoo protein (mSho) (Uniprot entry Q8BWU1) in a pSPORT1 plasmid 
was obtained from MRC Geneservice, the cDNA of mouse PrP (mPrP) (Uniprot entry P04925) 
from the Caughey lab (75). 
Plasmid vectors of the Sleeping Beauty Transposon based gene delivery system (SB CAGx100 
(76), pSB-CAG-Puro (77)) and the pRRL lentiviral vectors (pRRL-EF1-mCherry, pRRL-EF1-
EGFP (78))  were kind gifts of Dr. Zsuzsa Izsvák and Dr. Zoltán Ivics and of Dr. Katalin Német, 
respectively. 
DNA fragments were isolated from agarose gel using Macherey-Nagel NucleoSpin kit and 
plasmids were purified with QiaGen Miniprep kits. 
DNA oligonucleotides were bought from Microsynth AG (http://microsynth.ch). For the 
sequences of the oligonucleotides used for PCR and linker ligation see Appendix Table 2. 
All plasmids were constructed with standard molecular biology techniques, briefly as follows. 
The correct sequences for the expression cassettes in all plasmids generated in this study were 
confirmed by Sanger sequencing (Microsynth AG).  
All other reagents and chemicals were purchased from Sigma-Aldrich. 
 
DNA linker hybridization 
Short DNA fragments were inserted into plasmid vectors in the form of short DNA linkers. 
DNA linkers were hybridized from their respective oligo-pairs in PCR in the following 
hybridization mixture: 
2 l restriction enzyme buffer 
9 l forward oligo (1 mM) 
9 l reverse oligo (1 mM) 
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The hybridization mixture was heated to 95 °C in PCR machine for 5 minutes then cooled to 
25 °C with a -0.7 °C/minute cooling speed. Hybridized DNA linkers were either used 
immediately in ligation or were stored at -20 °C. 
 
Preparation of Shadoo and PrP constructs 
The deletion of the central region (amino acid residues 105-125) of mPrP in the pcDNA3 vector 
and the introduction of a silent mutation for removing the XhoI restriction site of the mSho 
cDNA in the pSPORT1 vector were carried out using QuikChange site directed mutagenesis 
protocol (Stratagene) with the following oligos: Delta105-125for and Delta105-125rev, 
XhoImutator5 and XhoImutator3, respectively. The removal of XhoI restriction site from mSho 
cDNA was carried out by Krisztián Kovács. Subsequently, XhoI-mutated mSho cDNA was 
PCR-amplified, using mShoBamHI5 and XhoISho3 primers and cloned to the pcDNA3 vector 
between BamHI and XhoI restriction sites. 
The deletion of the Shadoo HD (aa 62-71) was carried out with QuikChange site directed 
mutagenesis using the following mutagenesis primers ShoHDfor and ShoHDRev. 
The replacement of Shadoo HD with PrP HD in Shadoo was carried out, briefly as follows. The 
DNA linker coding the mPrP HD (amino acids 113-133) was ligated between the PCR products 
coding the N- (amino acids 1-61) and C-terminal (amino acids 78-147) fragments of the Shadoo 
protein and the ligation was followed by the PCR amplification of the full DNA sequence 
encoding the chimeric protein Sho(1-61)-PrP(113-133)-Sho(78-147). The cloning of the 
chimeric protein [will be referred as Sho(PrPHD)] was carried out by Petra Bencsura. 
The Sho25-61 [(RXXX)8] and the ShoQXXX8 constructs were prepared by Péter Kulcsár 
(69).  
 
Preparation of Sleeping Beauty plasmid constructs 
The cDNA of the Enhanced Green Fluorescent Protein (EGFP) with a Kozak-sequence was 
cloned into the polycloning site of the pcDNA3 eukaryotic expression vector, between BamHI 
and NotI restriction sites. The whole expression cassette containing the CMV-IE promoter and 
EGFP followed by a BGH PolyA signal was amplified from the vector by PCR with the 
following primers: ApoICMV5 and ApoIBGH3. PCR fragments were purified and digested by 
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ApoI enzyme, and were cloned into the EcoRI site of a Sleeping Beauty plasmid containing a 
puromycin resistance gene driven by a CAG promoter (pSB-CAG-Puro). The resulted plasmid 
is named pSB/GFP. 
The cDNA-s of wild type mPrP and mPrPCR were PCR-amplified with the primers PrPNheI5 
and PrPBamHI3 from the pcDNA3 vectors encoding the respective constructs. After 
purification, the amplified DNA fragments were digested with NheI and BamHI enzymes and 
inserted downstream of the CAG promoter into the pSB/GFP vectors, between the restriction 
sites of NheI and BglII, which also removed the cDNA of the Puromycin resistance gene. The 
resulted plasmids were named pSB/PrP and pSB/CR. Figure 3A shows the prepared pSB 
plasmid construct topologies. 
 
Preparation of lentiviral plasmid constructs  
A DNA linker (linker2-3048) containing the unique sites of AscI and BsiWI restriction 
endonucleases were cloned into the pRRL-EF1-mCherry or pRRL-EF1-EGFP lentiviral vectors 
between BsrGI and SalI sites. The modified pRRL vectors are called LV/mCh and LV/GFP. 
Expression cassettes containing the mPrP, mSho or ShoHD coding sequences after CMV-IE 
promoters were amplified by PCR from the pcDNA3 vectors encoding the respective constructs 
with the following PCR primers: V-CMV-PrP fw and V-CMV-PrP rev (for PrP), V-CMV-PrP 
fw and V-CMV-PA rev (for Sho) and V-dHD-fwd and V-dHD-rev (for ShoHD). In case of PrP 
and Sho expression cassettes the PCR products were digested and inserted between AscI and 
BsiWI sites of the modified pRRL-EF1-mCherry or pRRL-EF1-EGFP vectors and were called 
LV/PrP(R), LV/Sho(R) and LV/PrP(G). PCR product containing ShoHD coding sequence 
was inserted between the NdeI and SapI sites of the LV/Sho(R) vector, replacing wild type 
Shadoo cDNA. 
The DNA fragments harbouring the (RXXX)8 and QXXX8 mutations in Shadoo cDNA were 
cut from the respective plasmids by NdeI and Eco81I restriction enzymes and ligated between 
the same restriction sites in the LV/Sho(R) plasmid, replacing wild type Shadoo cDNA with 
the deletion mutant constructs. 
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The DNA fragment encoding Sho(PrPHD) construct was digested and inserted between NdeI 
and ApaI restriction sites in the LV/Sho(R) plasmid, replacing wild type Shadoo cDNA. 
The lentivirus plasmids containing the (RXXX)8, (QXXX)8, HD Sho and Sho(PrPHD) 
constructs are called LV/ShoRX(R), LV/ShoRQ(R), LV/ShoHD(R), and LV/ShoPrPHD(R) 
respectively. The pRRL vector constructs were designed by Petra Bencsura and Antal Nyeste, 
and the vectors were cloned by Petra Bencsura. Figure 3B shows the prepared pRRL plasmid 
construct topologies. 
Figure 3: Topologies of the plasmid 
constructs used in these studies. (A) 
Sleeping beauty plasmids used for 
integration of the expression cassettes. (B) 
pRRL plasmids used for lentivirus 
generation. IR-L, IR-R: left and right 
inverse repeats of SB. LTR-5’, LTR-3’: 5’ 
and 3’ long terminal repeats. CMV: CMV 
intermediate early promoter. CAG: CMV 
early enhancer/chicken beta actin promoter. 
EF1: elongation factor-1 promoter. EGFP: 
enhanced green fluorescent protein. PuroR: 
puromycin resistance gene. PrP-wt: wild 
type mouse prion protein. PrPCR: mouse 
prion protein missing the central region 
(aa. 105-125th). Sho: mouse Shadoo 
protein. Topologies of LV/ShoRX(R), 
LV/ShoRQ(R), LV/ShoPrPHD(R), and 
LV/ShoHD(R) plasmid vectors are identical 
to LV/Sho(R) and are not represented on the figure. 
 
Cloning of the recombinant Sho-PrP (rSho-PrP) fusion polypeptide 
The fusion polypeptide rSho-PrP was made by cloning a DNA fragment coding the mSho 
fragment 81-116th amino acids (TGSGWRRTSG PGELGLEDDE NGAMGGNGTD 
RGVYSYS) corresponding to the Abgent Sho antibody epitope, into a fragment coding for 
PrP(23-230) in a pET41 expression vector, between positions corresponding to the 93rd and 
94th amino acids of PrP. The mSho fragment was made by three DNA linkers (Sho-epi1, -2, -
3) with overlapping overhangs with phosphorylated 5’ ends and was ligated into the unique 
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Acc65I restriction enzyme site of the pET41-mPrP(23-230) plasmid vector. The cloning of 
rSho-PrP coding plasmid was carried out by Petra Bencsura.  
 
Expression, purification and refolding of the recombinant Sho-PrP fusion protein 
Plasmid pET41a encoding the rSho-PrP fusion polypeptide encompassing both PrP and Sho 
epitopes was transformed into competent E. coli BL21 (DE3) pLysS and after induction by 
isopropyl--D-1-thiogalactopyranoside it was expressed at 37 °C in inclusion bodies. Cells 
were harvested 8 hours after induction. Proteins were purified as follows: inclusion bodies were 
dissolved in buffer A [6 M guanidinium chloride (GdmCl), 100 mM Na2HPO4 400 mM NaCl, 
5 mM imidazole and 5 mM β-Mercaptoethanol, pH 8.0] and stirred overnight at 4 °C. After 
centrifugation, the soluble protein fraction was transferred to a nickel-nitriolotriacetic acid 
(NTA) agarose column. Before the oxidative refolding step, the column was washed with buffer 
B (10 mM Tris-HCl, 100 mM Na2HPO4, pH 8.0) containing at first 6 M GdmCl, then 1 M 
GdmCl. Oxidative refolding was performed in buffer B containing 1 M GdmCl, 10 mM 
glutathione (reduced), 5 mM glutathione (oxidized). To remove the non-specifically bound 
protein impurities, the column was washed with buffer B containing 50 mM imidazole. Elution 
was carried out with 50 mM sodium acetate, pH 4.1. Proteins obtained were stored at -80 °C in 
separate vials until use. A thawed vial was never refrozen. Protein concentration was 
determined by Bradford protein assay (see below). Expression and purification of the rSho-PrP 
fusion protein was carried out by István Vida and was the fusion protein was tested by Antal 
Nyeste with western blotting. 
 
Cell lines, culturing, transfection and transduction 
Origins of cell lines used in the studies 
Zpl2-1 mouse hypothalamic cell line was a kind gift of Y.S. Kim (79). 
SH-SY5Y human neuroblastoma cell line was from ATCC (ATCC CRL-2266TM) 
HEK293 human embryonic kidney cell line from Gibco (11631-017).   
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Maintenance of cell cultures 
Each type of cell was cultured in high-glucose Dulbecco’s Modified Eagle Medium (DMEM) 
complemented with 10% heat inactivated fetal bovine serum (FBS) and 100 units/ml Penicillin 
and 100 g/ml Streptomycin, at 37 °C in a humidified atmosphere with 5% CO2. Cells were 
passed at 90-95% confluence at 1:10 splitting ratios (SH-SY5Y and HEK293) or 1:20 splitting 
ratio (Zpl2-1). 
Vials of cells were frozen in -80°C overnight then stored in liquid nitrogen. Freezing DMEM 
contained 10% DMSO, 55% FBS and 40 units/ml Penicillin and 40 g/ml Streptomycin. 
All types of cells were regularly tested for mycoplasma contamination. SH-SY5Y lines were 
maintained till 20th passage number then new vials were thawed. 
 
Establishment of stable expression with Sleeping Beauty transposon system. 
The Sleeping Beauty synthetic Tc1-like DNA transposon is a Class II or DNA transposon. DNA 
transposons are excised from the DNA and reinserted into the host, thus their mechanism of 
propagation is cut and paste. Sleeping Beauty was reconstructed in 1997 and became one of the 
transposon-based tools that can be used for gene delivery in vertebrate model system (80, 81). 
The Sleeping Beauty (SB) gene delivery system consists of two plasmid vectors, one plasmid 
(SBx100) encoding the transposase, and the other (pSB) contains the terminal inverse repeat 
(IR) sequences with the to-be-inserted DNA sequence between the repeats. 
For transfection purposes 1*105 Zpl2-1 or SH-SY5Y cells were seeded on multiple wells of 6-
well plates. The transfection was carried out at 50-70% confluence, using a mixture of 3 g of 
one of the pSB constructs encoding either only GFP (SB/GFP), or GFP and WT-PrP (SB/PrP) 
or GFP and PrPCR (SB/CR) and 1 g of SBx100 plasmid, encoding a functional Sleeping 
Beauty Transposase, with TurboFect transfection reagent, in accordance with the 
manufacturer’s manual. 
 
Establishment of stable expression with pRRL lentiviral system. 
For lentiviral constructs pRRL, a third generation transfer vector was used (82). 
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In case of lentiviral transductions, the lentiviruses were generated and the virus titers were 
determined in the Hungarian National Blood Transfusion Service’s lentiviral facility. The 
transduction of SH-SY5Y and HEK293 cells were carried out briefly as follows.  
3*104 cells were seeded on 24 well plates. 24 hours after seeding medium was removed and 
replaced by fresh medium containing polybrene (60 g/ml) and lentivirus for 24 hours. 
Transductions were carried out at multiplicities of infections (MOI) 1 to 5. After the removal 
of the transduction medium cells were cultured in normal growth medium and were kept in 
quarantine for 3 passages. 
Conditions with the highest MOI were maintained for experiments, where cells remained viable 
and showed no morphological changes or decreased duplication rates. Transductions of SH-
SY5Y cells were carried out by Mónika Bácskai and Áron Szepesi. Transduction of HEK293 
cells was carried out by Antal Nyeste. 
 
Fluorescence-activated cell sorting (FACS) was used to separate cells with stable transgene 
expression in the transfected or transduced cell populations based on the expression of the 
fluorescent marker. In case of transfection with the Sleeping Beauty constructs, the EGFP 
positive cells were sorted at 3 and 14 days post-transfection. In the case of transduced cells, 
mCherry positive, or mCherry and EGFP double positive cells were sorted 7-10 days post-
transduction. 
EGFP and mCherry positivity were examined at every passage and experiments were carried 
out on cultures in which at least 90% of the cells expressed the required fluorescent markers. 
In parallel with the execution of the experiments, the expression levels of the transgenes were 
determined by immunoblotting technique. Cell sorting was carried out by György Várady. 
 
Cell viability assays 
Detection of apoptosis caused by serum deprivation or PrPCR expression in Zpl2-1 cells 
Spontaneous toxicity conferred by PrPCR, as well as the effect of serum deprivation on the 
various transgene-expressing cells, were assayed using Cy5 conjugated annexin-V and 7-
aminoactinomycin D (7-AAD). 
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Zpl2-1, Zpl/GFP, Zpl/PrP and Zpl/CR cells were seeded on 24 well plates at 3*104 cells/well 
density. 24 hours after seeding, cells were washed twice with FBS-free high-glucose DMEM 
to remove dead/unattached cells and any residual FBS from the well before the incubation in 
FBS-free DMEM (completed with 100 units/ml Penicillin and 100 g/ml Streptomycin), for 
either 48 or 72 hours. Each condition was tested in triplicates and the experiment was carried 
out three times. 
After serum deprivation, cells were processed for flow cytometry analysis. The medium 
removed from the cells was placed into FACS tubes, then the cells were trypsinized and 
transferred into the tubes containing their corresponding media. This way many of the cells that 
were dead and floating were included in the measurement. Cells were washed twice with PBS, 
and were resuspended in 1x annexin binding buffer at 106 cells/ml concentration (10x Binding 
buffer: 0.1 M HEPES (pH 7.4), 1.4 M NaCl, 25 mM CaCl2) containing Cy5-conjugated 
annexin-V (BD Pharmigen; 559934. used in 1:100 dilution) and 7-aminoactinomycin-D (7-
AAD, Sigma-Aldrich; A9400-1MG, used in 0.5 g/l concentration). 
30000 cells were counted from each sample and three groups of single-cells were identified: 
annexin and 7-AAD double negative i.e. living cells, annexin-positive and 7-AAD negative 
early apoptotic cells, and 7-AAD positive dead cells. For statistical analysis the percentage of 
viable cell populations (double negative) were determined and compared after 0, 2 or 3 days of 
serum deprivation.  
 
Analysis of drug hypersensitivity caused by PrPCR and Shadoo 
Cells stably transfected or transduced were seeded onto 96 well flat bottom plates at 3*104 
cells/well density (SH-SY5Y cells) or 1*104 cells/well density (HEK293 cells). 24 hours after 
seeding, the medium was changed to fresh medium containing serial dilutions of various drugs: 
Zeocin or G418 treatments were administered for 48 hours, and puromycin treatment for 24 
hours. The measurement of PrPCR-induced Zeocin hypersensitivity (Figure 10A, B) was 
carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), all 
other cell viability assays were carried out using PrestoBlue reagent according to the 
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manufacturers protocol, briefly as follows. Cell viability assays on SH-SY5Y cells with Presto 
Blue reagent were carried out by Petra Bencsura and Antal Nyeste as indicated in captions. 
 
MTT assay (83) is a colorimetric assay. The tetrazolium-ring of the MTT molecules is cleaved 
by the dehydrogenase enzymes of the mitochondria, reducing the MTT into a formazan dye that 
forms insoluble crystals in the cells. Since it requires mitochondrial function, it measures only 
the living cells. The signal generated correlates with mitochondrial activity and the number of 
living cells. 
After drug treatment, the medium was changed to PBS containing 0.5 g/ml MTT and plates 
were placed back into the cell culture incubator. After 4 hours of incubation, MTT solution was 
carefully removed and the converted formazan crystals were solubilized in acidic isopropanol 
(isopropanol:1 N HCl, 9:1) and the absorbance of the solution was measured at 560 nm. 
 
PrestoBlue (PB) assay is based on the intracellular reduction of resazurin to resorufin by the 
mitochondrial enzymes, which can be detected with colorimetry or fluorimetry. PB assay has 
several advantages over the classic MTT assay (84): Resazurin is stable, and unlike MTT, is 
not toxic to the cells, so it allows continuous monitoring of the same cells. In addition, PB assay 
is much faster than the MTT assay, and its sensitivity is higher. 
After the drug treatment the medium was changed to PBS containing 5% PrestoBlue and cells 
were placed back for 60 minutes into the CO2 incubator before measuring fluorescence with a 
Perkin Elmer Enspire Multimode Plate Reader (excitation: 555 nm, emission: 585 nm).  
Analysis of cell proliferation was carried out using 96-well plates and PrestoBlue assay. About 
4 hours after seeding, when cell attachment was confirmed by microscopy analysis, the 
fluorescence in 4 wells of each cell type was measured in order to be used as initial values. 
After every 24 hours for 8 days 4-4 wells of each cell were measured and the measured 
fluorescence values were normalized to the initial values to estimate the change in the number 
of cells. We were unable to calculate EC50 values from our curves, instead, based on previous 
articles of this field in the literature, we chose the viability values of a Zeocin and a G418 
concentrations from the middle of the dilution series for comparison and statistical analysis. 
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Immunocytochemistry 
Immunocytochemistry procedures 
Cells were seeded on Labtek-II 8-well slides (5*104 cell/well density) or on 96 well plates at 
1.5*104 cells/well density for phosphorylated Histone 2AX (-H2AX) detection. 24 hours after 
seeding cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes at room 
temperature (RT), washed 3 times in immunofluorescence washing (IF) solution (0,2% bovine 
serum albumin, 0,1% Triton-X 100 in PBS) followed by blocking and permeabilization (5% 
bovine serum albumin, 0.5% Triton-X 100 in IF solution) for 10 minutes at RT. 
Cells were washed again 3 times in IF solution before applying the primary antibody (SAF32 
anti-PrP mouse IgG for PrP staining, and purified anti H2AX.phospho antibody for -H2AX 
staining) for 1 hour at RT. 
The cells were then washed once by IF solution, and the secondary antibody was applied for 30 
minutes at RT. From the application of secondary antibodies, slides and plates were kept in 
dark. Cells were washed 3 more times for 10 minutes then for overnight. Nuclei were stained 
with DAPI for 10 minutes at RT (1 M DAPI in PBS) before microscope analysis. 
Detection of anti-PrP immunocytochemistry 
The cells were observed using an Olympus FV500-IX Confocal Laser Scanning Microscope, 
with a PLAPO 60x (1.4 N.A.) oil immersion objective (Olympus). DAPI, EGFP, mCherry and 
Alexa Fluor 647 fluorophores were excited at 405, 488, 543 and 633 nm, respectively. Emission 
detection ranges were 430-460 nm (DAPI), 505-525 nm (EGFP), 560+ nm (mCherry) and 660+ 
nm (Alexa Fluor 647), respectively. Confocal images were recorded with Olympus Fluoview 
5.0 software. Image acquisition settings (laser intensity, PMT settings, and confocal aperture 
size for each channel) were kept unchanged during confocal microscopy sessions. Images were 
captured in sequential scanning mode and using 1024x1024 pixel resolution. 
 
Anti--H2AX immunocytochemistry and high content screening 
Detection of Histone 2AX phosphorylation: SH-SY5Y cells expressing either Sho, PrPCR or 
their respective controls, mCherry or EGFP, were seeded on 96 well plates at 1.5*104 cells/well 
density. 24 hours after seeding the cells were subjected to 0, 20, 100 g/ml Zeocin, or 50 M 
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Etoposide in normal culture medium for 60 min at a 37 °C, then washed once with PBS and 
immunostained as described above. 
Image acquisition was performed with a ImageXpress® Micro XLS high-content screening 
system (Molecular Devices) using Nikon 10x Plan Fluor objective (NA=0.3). Blue and far-red 
fluorescence signals of DAPI and -H2AX for nuclei were detected using emission filters of 
447/60 nm and 692/40 nm, respectively, with 377/50 and 635/18 nm excitation filters, and 4-6 
fields of view were imaged per well. For analysis the cells were segmented on the basis of DAPI 
staining, and the percentage of -H2AX positive nuclei was determined using the MetaXpress 
software. At least 4000 cells were analysed per conditions. 
Image acquisition was carried out by Zoltán Hegyi. 
Image analysis – Microscopy images were analysed using the ImageJ 1.48v software with Bio-
Formats plugin. During image processing the lookup tables were always linear and covered the 
full range of the data.  
 
Immunoblotting 
Cells seeded on 100 mm cell culture dishes were harvested at 70-90% confluence after being 
washed once with PBS by scraping in 1 ml PBS. Cells were pelleted by centrifugation (3’, 
200xg) and re-suspended in ice cold lysis buffer (50 mM HEPES, pH 7.5, 0.2 mM EDTA, 10 
mM NaF, 250 mM NaCl, 0.5% NP-40, freshly supplemented with 1% Proteinase inhibitor 
cocktail, 1% Calpain inhibitor, 1 mM DTT). 
The total protein concentration was measured by using Bradford protein assay. 
Where needed, PNGaseF treatment was carried out on samples of 50-100 g total protein, 
according to the manufacturer’s protocol. Samples of 1-50 g total protein, depending on the 
necessities of the experiment, were run on 15% denaturing SDS-PAGE and were blotted onto 
activated PVDF membrane, using a wet blotting system from Bio-Rad. 
The membrane was incubated for at least 1 hour in blocking buffer (Tris buffered saline 
supplemented with 1% Tween-20 (TBST) containing 5% non-fat milk powder), and primary 
antibodies were applied overnight, at 4 °C. Next day, after washing the membrane in TBST 3 
times for 10-10 minutes, HRP-conjugated secondary antibodies were applied to the membrane 
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for 60 minutes, followed by 3 times of washing in TBST and one time in distilled water. The 
proteins were visualized by adding chemiluminescent substrate for 1 minutes. 
Phosphatidylinositol-dependent phospholipase-C (PI-PLC) treatment 
Cells were seeded on 24 well plates. After reaching confluence, the PI-PLC treatment was 
carried out according to the manufacturer’s protocol. Briefly: cells were washed twice in PBS 
and the plate with cells having only PBS or PBS with PI-PLC (1 unit/ml PI-PLC) was rocked 
gently for 30 minutes at 4 °C. The supernatants were removed from the cells, centrifuged (5’, 
20000xg) to remove cells and debris and processed for SDS-PAGE [noted as “medium (M)” 
samples on figures]. The PI-PLC treated and untreated cells were harvested from the plates by 
scraping and were processed for SDS-PAGE [noted as “cell lysate (Cl)” samples on figures].  
 
Statistics 
Cell viability assays were done with 5 parallel samples for every condition. The number of 
surviving cells in case of each drug concentration was normalized to the number of cells 
receiving no drug treatments. For statistical analysis one concentration was chosen from each 
drug-treatment: 6.25 g/ml for Zeocin, 250 g/ml for G418 and 1.6 g/ml for puromycin in 
case of SH-SY5Y cells and 50 g/ml for Zeocin, 250 g/ml for G418 in case of HEK293 cells. 
Statistical analysis (Normality tests, Student’s t-tests, One-way ANOVAs with two-tailed 
Dunnett’s or Tukey’s HSD post-hoc tests) was carried out on data from at least 3 independent 
experiments using SPSS Statistics v20 software. On plots, mean ± standard deviation (SD) 
values are shown. p values: * 0.01<p<0.05, ** 0.001<p<0.01, *** p<0.001.  
36 
 
 
 
Results 
Establishment of stable transgene expression in Zpl2-1, SH-SY5Y and HEK293 cell lines 
In order to establish stable expression of Shadoo, WT-PrP or PrPCR in various cell lines, 
we prepared a bicistronic system in Sleeping Beauty transposon based gene delivery system 
(SB) (85), and when additional transgene expression was required we chose a lentiviral 
approach (82), where an independent fluorescent protein, EGFP, or mCherry, expression was 
tightly coupled to the expression of our genes of interest. 
Our criteria for the expression system were: 
1) Easy detection of transgene expression. Immunocytochemistry is the most straightforward 
way of detecting a protein expression in situ, but we also wanted an easy and quick way, which 
can be used during cell culturing, to monitor the transgene expression. To achieve this we used 
fluorescent proteins as reporters, instead of antibiotic selection. We used fluorescent 
microscopy for regular monitoring of cells during maintenance of the cultures. The presence of 
the fluorescent reporters was used also to select the cells with stable transgene integration by 
using fluorescence-activated cell sorting (FACS). 
2) Usage of untagged Shadoo and PrP constructs. Fluorescent or epitope tagging of a protein 
may affect adversely the protein localization or function (i.e. loss of protein function), thus we 
established the expression of untagged proteins. 
3) Avoiding the positional effect of the transgene integration. We have worked with non-cloned 
cells where the randomized sites of the integrations eliminated the potential risk of positional 
effects. 
Assessing the extent of co-integration of the two expression cassettes between Sleeping Beauty 
transposon arms. 
At first, we tested the SB transposon system and found that the collective integration of the 
two expression cassettes between the transposon arms produced more than 95% coupling 
(Figure 4). Zpl2-1 cells were transfected with SH/GFP plasmids in the presence or absence of 
SBx100 transposase. After puromycin selection (6.25 g/ml puromycin, for 13 days) the 
percentage of GFP positive cells in the surviving, puromycin resistant population were tested 
with flow cytometry (Figure 4). Transposition of the two transgene resulted a more than 95% 
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coupling of the two transgenes (Figure 4B, D), whereas random integration of SB/GFP plasmid 
into the genome resulted only about a 40% co-integration of expression cassettes coding GFP 
and puromycin resistance genes (Figure 4C, D). 
 
Figure 4: The integration of 
the two expression cassettes 
between the transposon 
arms to be inserted by the 
Sleeping Beauty 
transposase is coupled. (A) 
Histogram of GFP positivity 
in untransfected, parental 
Zpl2-1 cells (B) Histogram 
of GFP positivity in Zpl2-1 
cells transfected with 
SH/GFP and SBx100 after 
13 days of puromycin 
treatment (C) Histogram of 
GFP positivity in Zpl2-1 
cells transfected with only 
SH/GFP after 13 days of 
puromycin treatment. (A-C) 
M1 markers were used to 
identify GFP positive cells. 
(D) Percentages of puromycin resistant, GFP positive cells under M1 markers on A-C 
histograms.  
 
Analysis of WT and CR PrP expression in cells established with Sleeping Beauty transposon 
system. 
Using SB system, we established stable expressions of PrPCR, PrP-WT and EGFP in Zpl2-
1 immortalized hippocampal Prnp-knockout cells (79), and in SH-SY5Y human neuroblastoma 
cells of very low endogenous PrP level (43, 86).  
Transgene expression was analysed by immunocytochemistry and immunoblotting in both 
Zpl2-1 (Figure 5) and SH-SY5Y (Figure 6) cells. The endogenous PrP expression was below 
the detection limit in SH-SY5Y by both immunocytochemistry and western blot technics 
(Figure 5B, 6B; lanes 1, 2).  In both cell types prion proteins localize predominantly on the cell 
surface and their expressions are coupled with the reporter EGFP (Fig 5A and 6A). Both WT 
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and CR PrP were glycosylated in both Zpl2-1 and SH-SY5Y cells and both non-glycosylated 
and glycosylated forms of the proteins were present (Figures 5B and 6B). The slight mobility 
shift caused by the deletion of the 21 amino acids of the central region (CR) can be detected in 
both Zpl/CR (Figure 5B lane 3 vs. 4) and SH/CR (Figure 6B lane 7 vs. 8) cells. 
 
    
Figure 5: Analysis of PrP-WT and PrPCR 
overexpression and localization in stably 
transfected Zpl2-1 cells. (A) Immunocytochemistry 
analysis of PrP overexpression and localization. 
Laser scanning confocal microscopy images, Nuclei 
(blue) and PrP-s (red) are stained by DAPI and 
SAF32 anti-PrP antibody, respectively. GFP is 
shown in green. Scale bar, 30 m. (B) Western blot 
analysis of PrP expression in Zpl cell lysates.  
 
 
The correct plasma membrane localization and the presence of the GPI-anchor of prion 
protein constructs were analysed by western blotting of cell lysates made from PI-PLC treated 
and non-treated SH-SY5Y cells (Figure 6C). In the PI-PLC treated cell lysates (upper panel, 
lanes 3 and 5) PrP signal was lower compared to the untreated samples (lanes 4 and 6), whereas 
the respective loading controls (upper actin panel) showed no such differences. Corroborating 
this, PrP appeared in the supernatant treated with PI-PLC (lower panel, lanes 4, 6). Note, that 
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while -actin showed cell contamination in all supernatant samples (lower actin panel), PrP 
coming from the cell contamination remained below detection limit in case of PI-PLC untreated 
samples. It can be concluded that both WT PrP (Figure 6C lanes 3, 4) and CR PrP (lanes 5, 6) 
are attached to the cell surface by GPI-anchor. 
 
  
Figure 6: Analysis of the glycosylation, localization and expression levels of prion proteins 
in SH/PrP and SH/CR cells. (A) Immunocytochemistry analysis of PrP overexpression and 
localization.  Laser scanning confocal microscopy images. Nuclei (blue) and PrP-s (red) are 
stained by DAPI and SAF32 anti-PrP antibody, respectively. Scale bar, 40 m. (B) Western 
blot analysis of PrP expression and glycosylation in SH-SY5Y cell lysates. Extracts from 
various cells as indicated above the lanes, were untreated (-) or treated (+) with PNGaseF and 
visualized using SAF32 anti-prion antibody. -actin was used as loading control (lower panel). 
(C) Western blot analysis of PrP cell surface localization. Extracts (cell lysate) and medium 
(medium) from various cells as indicated above the lanes, untreated (-) or treated (+) with PI-
PLC (upper panel).  -actin was used as loading control (lower panel) in case of cell lysates, 
and to detect cell contamination in supernatant medium samples. 
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Analysis of PrP and Shadoo expression in cells transduced with lentivirus 
Introduction of Shadoo or WT PrP transgenes into PrPCR expressing cells were carried out 
with lentiviral transduction, also the same approach was used for the establishment of SH/Sho 
and respective control cells. With no appropriate anti-Sho antibody for immunocytochemistry, 
the confirmation of correct localization and overexpression of Shadoo was carried out by 
immunoblotting. We found no morphological change (data not shown) or adverse effect on cell 
proliferation of SH/CR cells (Figure 7A) caused by the transduction of cells and stable 
expression of WT PrP or Shadoo. 
Figure 7: Analysis of the 
overexpression, glycosylation, 
localization and relative 
protein levels of prion and 
Shadoo transgenes in SH-
SY5Y cells. (A) Proliferation 
assay of the indicated cell lines 
using PrestoBlue reagent. 
Representative plot. 100% is 
the fluorescence value at day 
zero after attachment for each 
type of cell. (B) Western blot 
analysis of WT and CR PrP 
expression and glycosylation in 
SH-SY5Y cell lysates. (C) 
Western blot analysis of Sho 
expression and glycosylation in 
SH-SY5Y cell lysates. (B, C) Lysates from various cells as indicated above the lanes were 
untreated (-) or treated with PNGaseF (+) or without incubation (0). (D) Western blot analysis 
of Shadoo cell surface localization. Cl: Cell lysates, M: supernatant medium from SH/GFP (left 
panel) and SH/Sho (right panel) cells, incubated with (+) or without (-) PI-PLC. An 
intracellular protein, -actin was used as loading control for cell lysates, and as detection of 
cell contamination in medium samples. (B, D) Left and right panels are from the same X-ray 
film, corresponding to the left and right parts of the same membrane. (C, D) * marks a 
nonspecific band. As loading control -actin was used. (A) Proliferation assay was carried out 
by Petra Bencsura. 
 
The glycosylation of the Shadoo protein was determined using western blot after PNGaseF 
treatment of cell lysates. We found that Sho expressed in SH-SY5Y cells, like WT and CR 
PrP, showed complex glycosylation (Fig. 7B, C). PrPCR expression levels in SH/ΔCR, 
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SH/CR+mCh, SH/CR+PrP cells are comparable (Fig. 7B, lanes 6-8) after PNGaseF 
treatment, the C1 fragment (87) of Shadoo is more readily detectable (Fig. 7C, lane 6). 
Endogenous Shadoo expression is below the detection limit (Figure 7C, lanes 1-3). 
The cell surface localization and GPI-attachment of the Shadoo protein was verified by 
western blotting lysates of cells treated or not treated with PI-PLC (Figure 7D). The amount of 
Shadoo decreases below detection limit in the cell samples of PI-PLC treated cells (Figure 7D, 
lanes 5 vs. 7, upper panel), while the amount of an intracellular protein, -actin, remains 
unchanged (Figure 7D, lanes 5 vs. 7, lower panel). Shadoo remains below the detection limit in 
the medium samples. As Shadoo is a natively unfolded protein, it may be prone to proteolytic 
digestion in the medium, hence the lack of signal in the PI-PLC treated medium sample. 
SH/Sho, HEK/Sho cells and derivatives were established by subsequent lentiviral 
transductions. Shadoo and WT PrP expression were analysed by using western blot in both SH-
SY5Y (Figure 11A, B) and HEK293 (Appendix Figure 17) cells. 
Shadoo expression levels in SH/Sho and HEK/Sho were slightly lower than in their 
derivatives, SH and HEK/Sho+GFP and SH and HEK/Sho+PrP. In HEK293 cells endogenous 
WT PrP was detectable but the level of overexpressed PrP was significantly higher. 
The cells generated with either SB or LV are listed in Appendix Table 3, and the topologies 
of the plasmid constructs are shown on Figure 3. 
 
Comparison of the prion and Shadoo transgene expression levels in SH/CR+PrP and 
SH/CR+Sho cells. 
Since the antagonizing effects of the PrPCR, Shadoo and WT PrP depend on their relative 
concentration we compared the expression levels of these transgenes in the SH/CR+PrP and 
SH/CR+Sho cell lines. 
Serial dilutions of PNGaseF-treated cell lysates were analysed on western blot (Figure 8A). 
PrPCR and WT PrP expression level was comparable in SH/CR+PrP cells, and PrPCR 
expression was higher in SH/CR+Sho cell than in SH/CR+PrP cell. On the other hand, 
PrPCR expression levels were comparable in SH/CR+PrP and the parental SH/CR cells 
(Fig 7B, lanes 6-8). 
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Since direct comparison of the expression levels of two untagged proteins in a total cell 
lysate is impossible, the comparison of PrPCR and Shadoo was carried out by a bacterially 
expressed polypeptide (rSho-PrP) that contained epitopes of both anti-PrP and anti-Shadoo 
antibodies (Figure 8B). Serial dilution of PNGaseF-treated total cell lysate of SH/CR+Sho 
was blotted, along with a serial dilution of rSho-PrP on the same gel (Figure 8C). 
Bands representing the Shadoo and PrPCR proteins expressed in SH/CR+Sho (left side 
of the blot photo) were compared to bands representing the rSho-PrP polypeptide (on the right 
side of the blot photo). The estimated expression levels of PrPCR and Shadoo in SH/CR+Sho 
cells are similar.  
 
Figure 8: Comparison of prion 
protein and Shadoo expression 
levels in SH-SY5Y cells. (A) 
Comparison of overexpressed 
prion protein levels in serial 
dilutions of the indicated cell 
lysates using western blot 
analysis. Total protein of cell 
lysates loaded are indicated 
above the panels. (B) Schematic 
design of rSho-PrP recombinant 
polypeptide. (C) Comparison of 
PrPCR and Shadoo expression 
levels of SH/CR+Sho cells using western blot analysis. Total protein of cell lysates or purified 
rSho-PrP recombinant polypeptide loaded onto the gels are indicated above the panels. * marks 
a nonspecific band. (A, C) Left and right panels are from the same X-ray film, corresponding 
to the left and right parts of the same membrane. As loading control -actin was used. 
 
Effects of serum deprivation to WT and CR PrP expressing cells 
Based on previously published data (46, 47, 88) we investigated if the presence of WT or 
CR PrP changes the extent of apoptosis caused by serum deprivation in an immortalized cell 
line of hippocampal origin (Zpl2-1) (79), and the human neuroblastoma cell line SH-SY5Y. 
We investigated apoptosis in these cell lines by FACS analysis by labeling early apoptotic 
cells by annexin-V and dead cells by 7-AAD staining and we were unable to detect any 
significant protection conferred by WT PrP expression in serum deprived Zpl2-1 cells (Fig. 9). 
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Expression of PrPCR in Zpl2-1 cells did not increase number of apoptotic cells as tested 
by annexin staining in FACS (Figure 9, 0 day columns) and we could not detect any significant 
increase in cell death of SH-SY5Y cells as tested by Trypan blue staining (data not shown), 
despite spontaneous toxicity of HD deletion mutants of PrP have been reported in CGN (64) or 
SH-SY5Y (43) in sometimes devastating extent. We found no shocking decrease in the viability 
of any of the tested Zpl cells, but interestingly the viability loss of the Zpl/CR cells after 3 
days of serum deprivation turned out to be significant (Figure 9, yellow bars of 0 and 3 days). 
Whether this difference has any biological relevance is to be answered. 
 
Figure 9: Viability assays on Zpl2-1 cells 
expressing wild type or mutant PrP constructs. 
The percentage of living cell populations (annexin-
V and 7-AAD negative) were determined using flow 
cytometry and compared after 0, 2 or 3 days of 
serum deprivation in 3 independent experiments. 
100% is the sum of respective living (double 
negative), early apoptotic (annexin-V positive; 7-
AAD negative) and dead (7-AAD positive) 
populations for each cell lines and conditions. Bars 
represent mean ± S.D. **: p<0.01. 
 
 
Shadoo does not rescue Zeocin hypersensitivity caused by PrPCR in SH-SY5Y cells 
PrPCR is reported to cause hypersensitivity to Zeocin- and G418-related antibiotics in 
HEK, CHO, mouse NSCs and other cell lines, which is eliminated by PrP-WT co-expression 
(37, 38, 50, 89). 
We also detected increased Zeocin sensitivity in SH-SY5Y cells expressing of PrPCR but 
not in cells expressing WT PrP or GFP (Fig. 10A, B). To assess whether the co-expression of 
Shadoo would eliminate this phenotype caused by PrPCR we introduced Shadoo into SH/CR 
with lentivirus. Shadoo co-expression didn’t antagonize with the Zeocin hypersensitivity, 
where it was diminished by the co-expression of WT PrP (Figure 10C, D). As positive control 
WT PrP, for negative control only mCherry was introduced to the SH/CR cells. 
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Shadoo causes Zeocin and G418 hypersensitivity in various cell lines that is diminished 
by WT PrP co-expression 
Contrary to our expectations, Shadoo overexpression in SH-SY5Y cells caused 
hypersensitivity to both Zeocin and G418 (Figure 11) but not to puromycin (Figure 12), like 
PrPCR overexpression. Furthermore co-expression of WT PrP eliminated both the Shadoo-
induced Zeocin and G418 hypersensitivities (Figure 11). 
 
Figure 10: Overexpression of PrPCR causes Zeocin hypersensitivity in SH-SY5Y cells that 
is eliminated by WT PrP co-expression. (A, B) PrPCR makes SH-SY5Y cells hypersensitive 
to Zeocin. Cytotoxicity 
assays by MTT reagent. 
(A) Panel shows a 
representative 
experiment. Zeocin was 
applied from 0 to 100 
g/ml on various cells, 
as indicated, for 48 
hours. Values are 
means ± S.D. of 
parallels in the 
individual experiment. 
(B) Panel shows the 
average of 4 
independent 
experiments measured 
at 6.25 g/ml Zeocin 
concentration. (C, D) 
Co-expression of PrP-
WT but not Sho 
diminishes PrPCR 
caused Zeocin 
hypersensitivity. 
Cytotoxicity assay by 
PrestoBlue reagent. (C) Representative experiment carried out at Zeocin concentrations 
between 0-100 g/ml Zeocin on various cells as indicated, for 48 hours. Values are means ± 
S.D. of replicas. (D) Bars show the means ± S.D. of cell viabilities measured at 6.25 g/ml 
Zeocin concentration in n=3 independent experiments. (A-D). 100% is the absorbance (A, B) 
or fluorescence (C, D) values of untreated cells of each cell type. (B, D) Samples were 
compared to the first column of each diagram (B: SH-SY5Y, D: SH/CR), * p=0.04, *** 
p<0.001. 
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We compared Zeocin and G418 hypersensitivity in different cell types – SH-SY5HY and 
HEK cells and we got similar results. 
According to Western blot analysis SH/Sho+GFP or SH/Sho+PrP cells have slightly higher 
Shadoo expression than the parental SH/Sho cells (Figure 11A) and WT PrP can be detected 
only in SH/Sho+PrP cells (Figure 11B) verifying that the presence of WT PrP and not the lack 
of Shadoo expression is responsible for the elimination of G418 and Zeocin hypersensitivity in 
SH/Sho+PrP cells. 
 
Figure 11: Overexpression of Shadoo causes Zeocin and G418 hypersensitivity in SH-SY5Y 
cells could be eliminated by WT PrP co-expression.  
(A, B) Western blot analysis of Shadoo 
expression (A) and PrP expression (B) in 
PNGaseF treated extracts from SH cells. * 
marks a nonspecific band. -actin was 
used as loading control. (C, D) 
Cytotoxicity assays by Presto blue after 
48 hours of Zeocin treatment. (C) 
Concentration dependence of Zeocin 
cytotoxicity is shown in a representative 
experiment in SH-SY5Y cell types as 
indicated. (D) Differences in the viability 
of compared cell types was characterized 
at a selected concentration of Zeocin. 
Columns show the means ± S.D in 4 
independent experiments.  (E, F) 
Cytotoxicity assays by Presto Blue after 
48 hours of G418 treatment. (E) 
Concentration dependence of G418 
cytotoxicity is shown in a representative 
experiment in cell types as indicated (F) 
Differences in the viability of compared 
cell types was characterized at a selected 
concentration of G418. Columns show 
the means ± S.D. in 3 independent 
experiments. (C-F) Viability is given as 
percentage of non-treated controls. * 
p<0.05, ** p<0.01, *** p<0.001.  
(C, E) Cytotoxicity assays on SH-SY5Y 
cells were carried out by Petra 
Bencsura. 
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These phenomena were also observed in HEK293 cells. HEK/Sho cells, which overexpress 
Shadoo protein (Appendix Fig. 17A) were more sensitive to Zeocin (Appendix Fig. 17C, D) or 
G418 (Appendix Fig. 17 E, F) than HEK/mCh cells and the hypersensitivity to both drugs could 
be eliminated by the co-expression of wild type PrP (Appendix Fig. 17). It should be mentioned 
that low endogenous WT-PrP level of HEK293 cells were not able to overcome the sensitizing 
effect of Shadoo. 
 
Figure 12: Neither SH/Sho, nor 
SH/CR cells are hypersensitive to 
puromycin. (A) Representative 
experiment carried out at puromycin 
concentrations between 0-2 g/ml on 
various cells as indicated. (24 hours 
treatment) (B) Bars show the means 
± S.D. of cell viabilities measured at 
1.6 g/ml puromycin concentration 
in n=6 independent experiments. 
Cytotoxicity assays were carried out by Petra Bencsura. 
 
To assess the dependency of drug hypersensitivity upon Shadoo expression levels, three 
subpopulations of SH/Sho cells were generated with low, medium or high Shadoo levels by 
sorting cells for the related GFP fluorescence (Figure 13A). 
The G418 hypersensitivities of the SH/Sho subpopulation correlated to their relative Shadoo 
expression (Figure 13B, C) 
 
Shadoo, like PrPCR modulates the initial uptake of Zeocin 
It was shown that PrPCR increases the initial uptake of drugs (37). In our experiments we 
investigated whether Shadoo is similar to PrPCR in this respect or not. Zeocin causes double 
strand breaks in DNA, triggering the recruitment and phosphorylation of Histone 2AX at the 
break points that can be detected by immunocytochemistry (37, 90). 
Using High Content Screening (HCS) microscopy we compared the -H2AX positivity in the 
nuclei of SH/CR and SH/Sho cells to their respective controls (SH/GFP and SH/mCherry) after 
60 minutes of Zeocin treatment (0, 20 or 100 g/ml). As a positive control of -H2AX staining 
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we used etoposide, a cytotoxic drug that causes double strand breaks by inhibition of DNA re-
ligation by topoisomerase II (91). 
 
 
Figure 13: Shadoo induces G418 hypersensitivity in a dose dependent manner (A) Western 
blot comparison of relative Shadoo protein levels in SH/Sho cell lines sorted by FACS for 
related GFP levels. Western blot analysis of extracts from SH/Sho-low, SH/Sho-medium, 
SH/Sho-high as well as the parental SH/Sho and SH-SY5Y cells. * marks a nonspecific band. 
-actin was used as loading control. (B) Cytotoxicity of G418. Representative experiment 
carried out at G418 concentrations from 0 to 1000 g/ml on cells with different Shadoo levels. 
Values are means ± S.D. of corresponding replicas within the experiment.  (C) Bars show the 
means ± S.D. of cell viabilities measured at 250 g/ml G418 concentration in n=3 independent 
experiments. For testing significance, values were compared to the control, SH-SY5Y cell line 
and bars connected with brackets were also compared using Tukey’s HSD post-hoc test. * 
p<0.05, ** p<0.01, *** p<0.001 (B, C) 100% is the fluorescence values of untreated cells for 
each cell type. (B, C) Cytotoxicity assays were carried out by Petra Bencsura. 
 
We observed an increased number of -H2AX positive nuclei in SH/CR cells compared to 
SH/GFP cells (Fig. 14A) consistently with earlier reports (37). Similarly, a substantial increase 
could be seen in the number of -H2AX positive nuclei in SH/Sho cells (Fig. 14B), however, 
this effect was less pronounced in (~20% vs. ~50% -H2AX positive nuclei in SH/CR). 
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Figure 14: Detection of Histone 2AX-phosphorylation caused by Zeocin treatment. . (A, B) 
-H2AX positive nuclei was measured relative to total nuclei counted in (A) SH/GFP and 
SH/CR or (B) in SH/mCherry and SH/Sho cells, in untreated and Zeocin treated samples (20 
or 100 g/ml for 60 minutes) in n=3 independent experiments. -H2AX positivity of cells that 
received the same treatment was compared with independent samples Student’s t-tests. **: 
p<0.01. (C) Comparison of Shadoo and PrPCR expression in SH/Sho and SH/CR cells using 
the rSho-PrP polypeptide. Western blot analysis of serial dilutions made from PNGaseF treated 
samples of total cell lysates of SH/Sho and SH/CR and from rSho-PrP polypeptide. * marks a 
nonspecific band. -actin was used as loading control. HCS analysis was carried out by Zoltán 
Hegyi and Antal Nyeste. 
 
As both Shadoo and PrPCR induce drug hypersensitivities in a dose dependent manner the 
difference in sensitivities might be caused by a relative low Shadoo expression, thus we 
compared the levels of Shadoo and PrPCR in their respective cell lines, using the rSho-PrP 
fusion peptide and found that Shadoo expression in SH/Sho cells were even higher compared 
to that of PrPCR in SH/CR cells (Fig. 14C). These results suggest that both Shadoo and 
PrPCR increase the uptake of Zeocin, although Shadoo might be less effective in this respect. 
 
Searching for important regions of Shadoo protein in drug hypersensitivity effect. 
The CC1 domain is essential for both toxic and protective activities of the prion protein (38, 
92). In order to examine whether the similar, positively charged N-terminal domain of the 
Shadoo protein [(RXXX)8 motif, (69)] is involved in the drug sensitizing activity of the protein, 
we established SH-SY5Y cells stably expressing either Shadoo mutant lacking the amino acid 
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residues from 25 to 61th [Sho(RXXX)8] or another Shadoo construct where the (RXXX)8 
arginines were changed to glutamines [Sho(QXXX)8]. 
We found that both Shadoo constructs are correctly localized on the cell surface, attached to 
the plasma membrane with GPI-anchors (Figure 15A) and that they are N-glycosylated (Figure 
15B). The mobility shift caused by the deletion of the (RXXX)8 motif is also detectable after 
deglycosylation (Figure 15B lanes 2 vs. 3). According to lanes 3, 7 and 11, their expression 
levels of the (RXXX)8 mutant Shadoo constructs were higher than that of the wild type Shadoo. 
 
Figure 15. The presence 
of the (RXXX)8 domain 
is necessary for the drug 
sensitizing activity of 
the Shadoo protein. (A) 
Western blot analysis to 
investigate the cell 
surface localization of 
(RXXX)8 domain mutant 
Sho construct. Cl: Cell 
lysates, M: medium 
from WT, RXXX)8 and 
(QXXX)8 Sho expressing 
cells, incubated with (+) 
or without (-) PI-PLC 
(upper panel). An 
intracellular protein, -
actin was used as loading 
control for cell lysates, 
and as indicator of 
cellular contamination 
of medium samples 
(lower panel). (B) Sho 
expression in different cell lysates after PNGaseF treatment. * marks a nonspecific band in 
both panels. (C, D) Cytotoxicity assays by Presto blue after 48 hours of G418 treatment. 100% 
is the fluorescence values of untreated controls of each cell line. (C) Concentration dependence 
of G418 cytotoxicity is shown in a representative experiment in cell types as indicated (D) 
Differences in the viability of compared cell types was characterized at a selected concentration 
of G418. Columns show the means ± S.D. in 3 independent experiments. Samples were 
compared to SH-SY5Y cells, *** p<0.001.  
(C, D) Cytotoxicity assays were carried out by Petra Bencsura and Antal Nyeste. 
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After 48 hours treatment with G418 SH-SY5Y cells expressing either (RXXX)8 mutant Sho 
constructs showed no elevated sensitivity to the drug, compared to the parental SH-SY5Y cells, 
while cells expressing wild type Shadoo were significantly more sensitive (Figure 15C, D). 
 
The importance of the Hydrophobic Domain (HD) was studied also by the expression of a 
Shadoo construct lacking HD motif (62-77th amino acids; ShoHD) in SH-SY5Y 
(SH/ShoHD), and by another Shadoo construct in which HD (amino acids 62-77) was replaced 
by the PrP HD motif (amino acids 113-133) [Sho(PrPHD)]. We found both proteins were 
correctly localized at the cell surface by a GPI-anchor (Figure 16A, C) and both were complex 
N-glycosylated (Figure 16B, D), although, ShoHD expression was significantly lower than 
that of the WT Shadoo (Fig. 16A lanes 1 vs. 3). 
We detected increased sensitivity to G418 in cells expressing ShoHD (similar to SH/Sho) 
despite its low expression, but the replacement of Sho HD to PrP HD suppressed greatly the 
sensitizing effect (Figure 16 C, D). Slight hypersensitivities could be observed only at the two 
highest concentration of G418. 
 
Our results therefore suggested that the arginines in the N-terminal (RXXX)8 motif are 
necessary for the drug sensitizing activity of the Shadoo protein but the presence of the 
Hydrophobic Domain (HD) is not required. 
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Figure 16. The hydrophobic 
domain (HD) of the Shadoo 
protein isn’t necessary for the 
drug sensitizing activity but 
modulates the effect. A: Western 
blot analysis of ShoHD cell 
surface localization. Cell lysates 
from WT and HD Sho 
expressing SH-SY5Y cells, were 
incubated with (+) or without (-) 
PI-PLC (upper panel). An 
intracellular protein, -actin was 
used as loading control for cell 
lysates (lower panel). Left and 
right panels are from the same X-
ray film, corresponding to the left 
and right parts of the same 
membrane. (B) Western blot 
analysis Shadoo glycosylation in 
WT or HD Sho expressing SH-
SY5Y cell lysates treated (+) or 
not treated (-) with PNGaseF. (C) 
Western blot analysis of 
Sho(PrPHD) construct cell 
surface localization. Cell lysates 
from WT and Sho(PrPHD) 
expressing SH-SY5Y cells, 
incubated with (+) or without (-) PI-PLC (upper panel). An intracellular protein, -actin was 
used as loading control for cell lysates (lower panel). (D) Western blot analysis Shadoo 
glycosylation in WT Sho or Sho(PrPHD) expressing SH-SY5Y cell lysates treated with 
PNGaseF. (A-D) * marks a nonspecific band. (C, D) Cytotoxicity assays by Presto blue after 
48 hours of G418 treatment. 100% is the fluorescence values of untreated controls of each cell 
line. (C) Concentration dependence of G418 cytotoxicity is shown in a representative 
experiment in cell types as indicated (D) Differences in the viability of compared cell types 
were characterized at a selected concentration of G418. Columns show the means ± S.D. in 3 
independent experiments. Samples were compared to SH/ShoQXXX8 cells, *** p<0.001. 
(E, F) Cytotoxicity assays on SH/Sho(QXXX)8 and Sho(PrPHD) were carried out by Petra 
Bencsura and Antal Nyeste. 
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Discussion 
Almost a century passed since the discovery of the Creutzfeldt-Jacob Disease, but 
fundamental questions, such as how does the PrPC – PrPSc conversion contribute to the 
neurodegeneration in various forms of transmissible spongiform encephalopathies remained 
unanswered.  
Several pieces of evidence (18–21) support a hypothesis suggesting that the TSE-associated 
neurodegeneration is caused neither by the loss of a vital function of the PrPC nor by PrPSc 
merely gaining a novel, toxic function, but probably by the subversion or corruption of a non-
toxic function of the prion protein that leads to neurotoxic phenotype. Therefore investigating 
the numerous functions of the WT PrP and its mutants – especially those activities that 
participate in toxic or protective processes – might help to elucidate the role of this protein in 
the mechanism of neurodegeneration in TSE. 
In this work we established cell culture models that enabled us to investigate the protective 
and toxic characteristics associated with prion protein expression. 
 
Effects of WT and CR PrP on serum deprivation caused cell death 
There are several reports about the PrPC cytoprotective activity, that prevents the oxidative 
stress or serum deprivation caused death of neurons and other cells (46, 47, 88, 93, 94). It is 
also known that in TSE an increased oxidative stress occurs (95). All this suggests an impaired 
or altered protective function of the prion protein that possibly lead to neurodegeneration. 
Contrary to the published data about the cytoprotective activity of PrPC, we could not detect 
protection against serum deprivation conferred by the wild type prion protein when the protein 
was expressed in immortalized hippocampal-originated cell line. 
Although different cell types used in different studies may explain the observed differences 
our results are in line with a report where no robust cytoprotective effect of PrP was found in a 
similar cell culture model (96).  
While in our model WT PrP offered no protection, we found that the presence of PrPCR 
increased the sensitivity of the cells to serum deprivation. Although this sensitizing effect was 
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statistically significant and reproducible, it wasn’t too robust (about 15% decrease from day 0 
to day 3). 
The exact role of the PrP in the serum deprivation sensitivity of Zpl cells and effect of the 
examined deletion mutation in the protein is still not clear and further investigation is needed. 
 
Drug hypersensitivity caused by PrPCR and Shadoo 
Shadoo and PrPCR cause drug hypersensitivity by a similar mechanisms of action.  
Expression of prion protein variants lacking the central region or hydrophobic domains have 
been associated with harmful phenotypes in animal or cell culture models in the absence of wild 
type PrP. Even though the expression of these mutants causes severe toxicity in PrP null 
transgenic mice (33–35)  and in CGN cultures (64, 97), they show reduced effect (43, 98), or 
no effect (42, 96) when expressed in immortalized cell lines. The most obvious phenotype 
associated with the Shmerling or CR mutations in PrP-s in cell models is the drug 
hypersensitivity and the occurrence of spontaneous inward cationic currents (37, 39). Strong 
evidence supports that the same functional changes of PrPCR is behind these two phenotypes 
detected in different models (40). 
Shadoo is generally regarded as an analogue of the N-terminal domain of the WT PrP, 
showing similar cytoprotective features (43, 64) in models for exploration of the toxic and 
protective functions of the PrP. 
In the drug hypersensitivity model, however, we have found that Shadoo, instead of 
elimination of the PrPCR induced phenotype also increased drug hypersensitivity in a dose 
dependent manner which could be eliminated by co-expression of WT PrP in the cells similarly 
to the PrPCR induced alterations. 
The drug sensitizing effects of Shadoo and PrPCR proteins share further features, such as 
increased initial drug uptake or the similar drug selectivity of these proteins (Zeocin or G418, 
but not to puromycin). Furthermore, in our preliminary patch clamping experiments, Shadoo 
expression induced inward ionic currents similarly to PrPCR (data not shown). 
These similarities suggest overlapping mechanisms of action behind the analogous functions 
of the Shadoo and PrPCR, which is surprising, as the two proteins are sequentially different: 
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the only region that shows sequential homology between the Shadoo and PrPCR (hydrophobic 
domain) is missing from the latter one. 
It must be also noted that Zeocin uptake was less efficient in Shadoo expressing cells, even 
though Sho expression level was higher than that of PrPCR in the parallel SH/CR cells 
suggesting that the drug sensitizing functions of Shadoo and PrPCR are related but not 
identical. 
Similar differences were found between the effects of Shmerling mutant (PrP32-121 and 
PrP32-134) and CR PrP-s in multiple models. Shmerling and CR mutants of the PrP exhibit 
related neurotoxic phenotypes in mice, but both the severity and the relative amount of co-
expressed PrPC is different that is required to eliminate the toxicity. Furthermore Massignan 
and colleagues demonstrated that this difference between the various PrP mutants also exists in 
the drug sensitizing paradigm: PrPCR causes more severe drug hypersensitivity than 
Shmerling mutant PrP-s at similar expression levels (37). 
 
Importance of the (RXXX)8 motif in the drug sensitizing function of Shadoo 
The (RXXX)8 domain of the Shadoo is similar to the N-terminal charged cluster (CC1) of 
the PrP in respect of bearing several positively charged residues, although in the (RXXX)8 
domain the positive charges are not as stacked as in the CC1, but more spread out along the N-
terminus of the protein.  
CC1 is conserved from bird to mammals and was demonstrated to be essential for both 
protective and toxic phenotypes caused by the protein (38, 92), its deletion didn’t render the 
protein toxic, but disrupted both protective and toxic activities of the WT or CR PrP. 
The role of (RXXX)8 in the protective functions of the Shadoo protein hasn’t been explored, 
but this domain was found to be highly conserved among species and also being required of the 
nuclear accumulation of the Shadoo protein (69). 
Although in our experiments Shadoo mutants lacking the (RXXX)8 motif or when arginines 
of this domain replaced with glutamines had correct cell surface localization and glycosylation 
(as inferred by western blotting of PIPLC or PNGaseF treated samples), we found that cells 
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expressing these constructs exhibited no drug hypersensitivity, supporting the importance of 
the positively charged (RXXX)8 domain in the drug sensitizing function of the Shadoo. 
The PrP CC1 was described to be able to bind glycosaminoglycans (GAGs) and also act as 
a protein transduction domain (PTD) (40, 99). Based on their previous findings of drug 
hypersensitivity and spontaneous ionic currents, and the PTD activity of the CC1 domain, the 
Harris-group proposed a model where PrPCR is able to form transmembrane pores, through 
which such elevated uptake of drugs and spontaneous inward cationic currents may occur (40, 
99). 
There is no data in the literature about any GAG-binding or PTD-like activities of the 
(RXXX)8 domain. Since its function is currently unknown, further studies required to reveal a 
potential role in the pore forming mechanism. 
 
Importance of the hydrophobic domain of Shadoo in drug sensitization 
In previous studies it was demonstrated that the presence of the HD is required for various 
protective effects of the Shadoo, such as protection against toxicity of PrP32-121, or Doppel 
in CGN cultures (64) or against glutamate toxicity (43). This domain also acts as an interface 
of PrP binding (43, 100), and shows the highest sequential similarity to the analogous region of 
PrP. 
Our finding that the absence of the HD didn’t eliminate the sensitizing effect of the Shadoo 
protein, suggests that the Shadoo HD doesn’t play any essential role in the drug sensitizing 
function of the protein however its replacement with the prion protein HD greatly reduced this 
sensitizing effect. It raises the question, what is the difference between the behaviour of the two 
HD-s?  
PrP only exhibits ion channel forming activities, when the HD is removed from the protein, 
which suggests an inhibitory function of the PrP HD to this activity. 
As the decreased drug hypersensitivity in Sho(PrPHD) expressing cells cannot be explained 
by the impaired localization or posttranslational modification of the Sho(PrPHD), one can 
hypothesise that the differing drug sensitizing functions of WT Shadoo and Sho(PrPHD) 
expressing cells originate only in a difference between the HD-s of Shadoo and PrP. For 
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example, Shadoo HD may be an imperfect, “loss-of- function” PrP HD analogue that is not able 
to completely inhibit or keep the drug sensitizing/ionic current forming activities of the protein 
under control. 
Sho HD has no role in the inhibition of the drug sensitizing function of Shadoo, but if this 
domain has any other role related to this phenomenon is yet to be examined.  
 
Consequences of Shadoo-induced drug hypersensitivity 
Our finding that Shadoo (similarly to PrPCR) induces drug hypersensitivity is surprising 
and raises further questions. Among them the most interesting ones is how these phenotypes 
caused by Shadoo or PrPCR relate to the other toxic activities of the prion family members, 
and to the neurodegeneration occurring in TSE and AD? 
Relation with other PrPCR associated toxic phenotypes 
In the drug hypersensitivity model, Shadoo behaves similar to PrPCR. Instead of 
suppressing the deleterious effect of the toxic PrP mutant as Sho does in other models akin to 
WT PrP, it also causes drug hypersensitivity. This difference suggests that this activity of 
PrPCR is not related to other toxic phenotypes caused by it in transgenic PrP-null animal or 
CGN cultures. 
Relation with neurodegeneration occurring in TSE-s 
A handful PrP variants harbouring certain familial GSS or CJD-related point mutations in 
the CC2 or HD exhibit both of the drug sensitizing and ionic current generating activities (39, 
40). One of them is P101L, the mouse variant of the most common GSS-causing mutation of 
human PrP (P102L PrP) (101). Transgenic mice expressing P101L PrP on PrP+/+ background 
(with about 8:1 P101L:WT PrP ratio) develop spontaneous neurological dysfunctions and 
spongiform degeneration of brain tissue reminiscent of TSE.  Extracellular amyloid plaques are 
present in the brains of these mice, but PK-resistant PrP is not detectable (102). Note that similar 
phenotype was described in human GSS caused by P102L mutation, where clinical signs of 
neurodegeneration was present without any detectable PK-resistant PrPSc (103). 
Interestingly, the expression of P101L PrP on PrP0/0 background exhibited spontaneous 
clinical signs earlier in mice (102), suggesting a suppressing role of PrPC in the GSS animal 
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model, thus supporting a hypothesis that the function of the mutant PrP that manifests in 
increased drug sensitivity and inward cationic currents is probably behind some of the 
symptoms of GSS caused by certain mutations in PrP. 
While endogenous Shadoo protein level is dramatically decreased in some TSE-brains, the 
brain of P101L PrP expressing mice shows minimal decrease in Shadoo protein level (70), 
suggesting that unlike in other forms of TSE-s, Shadoo is present and thus has a chance to 
become involved in the P102L-caused GSS pathogenesis but whether it has any relevance in 
neurodegeneration occurring in that disease is yet to be found out. 
 
Relation to prnp null phenotypes in mice 
There is one more important aspect of the drug sensitizing/ionic current forming activity of 
Shadoo. If these activities of Shadoo and PrPCR are really related to one other and to some 
forms of GSS pathogenesis, then Shadoo expressing prnp-knockout mice should also exhibit 
some overt phenotypes. Contrarily to this, PrP null mice are viable and without such phenotype 
(104) but they show minor abnormalities (25, 26). It must be noted that endogenous Shadoo 
expression level is thought to be much lower than that of PrP, which might also contribute to 
the absence of a clear phenotype. 
Whether such abnormalities are related to the Shadoo expression on PrP null background 
has been examined only in case of the axonal demyelination, where it was found that the 
phenotype was not related to Shadoo (87). Whether the untested phenotypes are related to 
Shadoo expression or not, could be tested by crossing Shadoo-overexpressing mice (70) to a 
prnp-knockout background. 
 
Last, but not least, one must consider that it is very unlikely that Shadoo would have 
remained as such conserved protein as it is with a potentially toxic and uncontrolled function 
like the drug sensitizing/ionic current forming activity. Because of this it would be highly 
illuminating to understand its purpose under physiological condition and to understand the 
mechanisms that participate in the regulation of this function.  
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Summary of new findings 
Serum deprivation model 
1. We detected no protection provided by WT PrP against the apoptosis caused by serum 
deprivation. 
2. While PrPCR expression wasn’t lethal or toxic in Zpl2-1 cells, it made the cells slightly 
more sensitive to serum deprivation than control cells were. 
 
Drug hypersensitivity model 
1. We found that Shadoo induces hypersensitivity to Zeocin and G418 but not to puromycin 
in cells overexpressing the protein. 
2. Our results suggest that the mechanisms behind Shadoo and PrPCR-induced drug 
hypersensitivities are closely related. 
2.1. Shadoo and PrPCR sensitizes cells to identical antibiotics (Zeocin and G418 but not 
puromycin) in a dose dependent manner. 
2.2. Wild type PrP interferes with the G418 and Zeocin hypersensitivity caused by both 
Shadoo and PrPCR in SH-SY5Y and HEK293 cell cultures. 
2.3. Shadoo increases the initial drug uptake of the cell akin to PrPCR but with a lower 
efficiency.  
3. We identified a region of the mature Shadoo protein, the (RXXX)8 domain whose presence 
is essential for the drug-sensitizing activity of the Shadoo protein.  
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Appendix 
 
Oligo Name DNA sequence 
Delta105-125for AACAAGCCCAGCAAACCAGGCTACATGCTGGGGAG 
Delta105-125rev CTCCCCAGCATGTAGCCTGGTTTGCTGGGCTTGTT 
XhoImutator5 CGGCCGCGGAGGCGCACGAGGCAGTGCCCGG 
XhoImutator3 CCGGGCACTGCCTCGTGCGCCTCCGCGGCCG 
ApoICMV5 CGCGCGAAATTTCTGCTTCGCGATGTACGGG 
ApoIBGH3 GGCCCGAAATTTCCACCGCATCCCCAGCATG 
PrPNheI5 GCCGGGCTAGCCACCATGGCGAACCTTGGCTACTG 
PrPBamHI3 TACCACGGATCCTCATCCCACGATCAGGAAGATG 
mShoBamHI5 CCCGAAGGATCCGCCACCATGAACTGGACTGCTGCCACG 
XhoISho3 GGCGCGCTCGAGCTAAGGCCGAAGCAGTTCTAG 
Linker2-3048-fwd GTACAAGTGAGGGCGCGCCAAACATATGAAACGTACGAA 
Linker2-3048-rev TCGATTCGTACGTTTCATATGTTTGGCGCGCCCTCACTT 
V-CMV-PrP fw TTTGCAGGCGCGCCCGATGTACGGGCCAGATATACG 
V-CMV-PrP rev CACTATTGTACAGGGCCCTCTAGATGCATGCTCGAGC 
V-CMV-PA rev ATAGAGTGTACAACATCCCCAGCATGCCTGC 
Sho-epi1-fwd GTACAGGCTCTGGCTGGAGGAGGACCTCAGGGCCTGGAGAGCTA 
Sho-epi1-rev* AGGCCCTGAGGTCCTCCTCCAGCCAGAGCCT 
Sho-epi2-fwd* GGCCTGGAGGACGATGAGAATGGGGCAATGGGAGGC 
Sho-epi2-rev* TGCCCCATTCTCATCGTCCTCCAGGCCTAGCTCTCC 
Sho-epi3-fwd* AACGGAACCGACCGAGGAGTCTACAGCTACA 
Sho-epi3-rev GTACTGTAGCTGTAGACTCCTCGGTCGGTTCCGTTGCCTCCCAT 
ShoHDfor TACGGCTCCTCTCTGCGCGGCCTTGCTACCGGCTCT 
ShoHDrev AGAGCCGGTAGCAAGGCCGCGCAGAGAGGAGCCGTA 
V-dHD-fwd TTTCCCTCATGAACGTTATCCCCTGATTCTGTG 
V-dHD-rev AGCTCTGCTCTTCCTGATGTCCTCCTCCAGCCAGAGCC 
Table 2: The DNA oligos used in the cloning processes. Asterisks mark 5’ phosphorylation. 
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Cell culture name Introduced transgenes Parental Cell name Vector used 
Zpl/GFP EGFP Zpl2-1 pSB/GFP 
Zpl/PrP mPrP and EGFP Zpl2-1 pSB/PrP 
Zpl/CR mPrPCR and EGFP Zpl2-1 pSB/CR 
SH/GFP EGFP SH-SY5Y pSB/GFP 
SH/PrP mPrP and EGFP SH-SY5Y pSB/PrP 
SH/CR mPrPCR and EGFP SH-SY5Y pSB/CR 
SH/mCh mCherry SH-SY5Y LV/mCh 
SH/Sho mSho and mCherry SH-SY5Y LV/Sho(R) 
SH/CR+mCh mCherry SH/CR LV/mCh 
SH/CR+PrP mPrP and mCherry SH/CR LV/PrP(R) 
SH/CR+Sho mSho and mCherry SH/CR LV/Sho(R) 
SH/Sho+GFP EGFP SH/Sho LV/GFP 
SH/Sho+PrP mPrP and EGFP SH/Sho LV/PrP(G) 
SH/ShoRXXX8 mSho26-61 and mCherry SH-SY5Y LV/ShoRX(R) 
SH/ShoQXXX8 mSho(QXXX)8 and mCherry SH-SY5Y LV/Sho
RQ(R) 
SH/ShoHD mSho62-77 and mCherry SH-SY5Y LV/ShoHD(R) 
SH/Sho(PrPHD) mSho62-77PrP113-133 and 
mCherry 
SH-SY5Y LV/ShoPrPHD(R) 
HEK/mCh mCherry HEK293 LV/mCh 
HEK/Sho mSho and mCherry HEK293 LV/ Sho(R) 
HEK/Sho+GFP EGFP HEK/Sho LV/GFP 
HEK/Sho+PrP mPrP and GFP HEK/Sho LV/PrP(G) 
Table 3. Cells with stable transgene expression used in these studies. The given abbreviated 
names and the specifics for each type of transformant cell are listed in the columns.
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Figure 17: Overexpression of 
Shadoo causes Zeocin and 
G418 hypersensitivity in 
HEK293 cells could be 
eliminated by WT PrP co-
expression. (A, B) Western blot 
analysis of Shadoo expression (A) 
and PrP expression (B) in 
PNGaseF treated extracts from 
HEK cells. * marks a 
nonspecific band. -actin was 
used as loading control. (C, D) 
Cytotoxicity assays by Presto 
blue after 48 hours of Zeocin 
treatment. (C) Concentration 
dependence of Zeocin 
cytotoxicity is shown in a 
representative experiment in 
HEK293 cell types as 
indicated. (D) Differences in 
the viability of compared cell 
types was characterized at a 
selected concentration of 
Zeocin. Columns show the 
means ± S.D in 3 independent 
experiments.  (E, F) 
Cytotoxicity assays by Presto 
Blue after 48 hours of G418 
treatment. (E) Concentration 
dependence of G418 
cytotoxicity is shown in a 
representative experiment in 
cell types as indicated (F) 
Differences in the viability of 
compared cell types was 
characterized at a selected 
concentration of G418. 
Columns show the means ± S.D. in 3 independent experiments. (C-F) Viability is given as 
percentage of non-treated controls. * p<0.05, ** p<0.01, *** p<0.001. 
 
